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1.1	MYC	proteins	in	cancer,	an	overview	
	MYC	 proteins	 are	 a	 group	 of	 transcription	 factors	 that	 includes	 c-MYC,	N-MYC	and	 L-MYC.	 MYC	 transcription	 factors	 have	 highly	 homologous	 structures	 and	contain	 a	 bHLH/LZ	 (basic	 Helix-Loop-Helix/Leucine	 Zipper)	 domain:	 through	the	bHLH	domain	MYC	proteins	bind	 to	DNA,	while	 the	 leucine	 zipper	domain	allows	 dimerization	 with	 the	 Max	 co-factor;	 the	 heterodimer	 MYC/MAX	 binds	consensus	 sequences	 (CANNTG)	 named	 E-box	 in	 the	 regulatory	 regions	 of	 its	target	genes	and	recruit	transcriptional	co-factors	(1,	2).	Myc	 is	 considered	 a	 master	 regulatory	 transcription	 factor	 that	 has	 been	estimated	to	bind	to	over	10%	of	gene	promoters	in	different	cellular	types.	MYC	activates	 gene	 transcription	 through	 the	 release	 of	 the	 RNA	 polymerase	 II	 by	recruiting	 to	 the	 promoters	 the	 transcription	 elongating	 factor	 b	 (P-TEFb)	 (3),	but	 it	has	been	also	describes	 to	negatively	 regulate	 target	genes	 transcription	through	 the	 interaction	 with	 the	 transcription	 factors	 Myc	 interacting	 zinc	protein	1	(Miz-1)	or	SP1	(4,	5).		MYC	 family	 proteins	 are	 overexpressed	 in	 several	 cancers	 such	 as	 lymphoma,	melanoma,	multiple	myeloma	 and	neuroblastoma,	 as	well	 as	 colon,	 breast	 and	lung	cancers	 (6-9).	On	average,	70%	of	human	tumors	show	an	 increased	MYC	expression,	 feature	 that	 usually	 correlates	with	 high-grade	 premalignancy	 and	invasive	cancers,	and	associates	with	poor	prognosis	(10-13).	Pathological	MYC	over-expression	 is	 frequently	 achieved	 by	 transcriptional	 up-regulation	 due	 to	chromosomal	 translocation	 (14-18),	 gene	 amplification	 (19,	 20)	 or	 by	 virus	mediated	 insertional	mutagenesis	 (21,	 22).	Although	 the	 increase	 in	MYC	gene	copy	 number	 is	 not	 always	 related	 to	 MYC	 overexpression,	 the	 frequent	correlation	of	 this	 event	with	metastasis	 and	poor	 survival	of	patients	 indicate	his	direct	role	 in	many	human	cancers	(23).	MYC	overexpression	 is	 involved	 in	all	 aspects	 of	 tumor	 cell	 biology	 by	 promoting	 proliferation,	 cell	 survival,	differentiation	 blockage,	 angiogenesis	 and	 metastasis.	 Furthermore,	 cell	proliferation,	metabolic	boost	and	survival	promoted	by	MYC	produce	cells	with	highly	 unstable	 genomes	 and,	 consequently,	 a	 higher	 chance	 to	 accumulate	additional	 mutations,	 which	 may	 contribute	 to	 tumor	 progression	 and	maintenance.	These	processes	provide	cancer	cells	with	a	long-term	proliferative	
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advantage;	 on	 the	 other	 hand	 each	 of	 them	 represents	 a	 possible	 target	 to	develop	 innovative	 therapeutic	 approaches	 to	 counteract	 Myc	 overexpressing	tumors.		
1.1.1	Cell	proliferation	and	metabolism	MYC	 has	 a	 critical	 role	 in	 different	 physiological	 processes	 and	 its	overexpression	may	alter	transcription	of	its	target	genes	involved	in	cell	cycle,	replication,	metabolism,	 and	 RNA	 biogenesis.	 MYC	 has	 the	 ability	 to	 stimulate	tumor	progression	by	promoting	proliferative	and	pro-survival	pathways,	which	could	 give	 cancer	 cells	 a	 long-term	 advantage.	 MYC	 proteins	 can	 profoundly	influence	cell	cycle	progression.	It	has	been	shown	that	MYC	ectopic	expression	is	 sufficient	 to	drive	 the	quiescent	 cells	 in	S	phase,	 independent	of	 any	growth	stimulus	 (24,	 25).	MYC	 promotes	 cell	 cycle	 progression	 directly	 by	 controlling	cell	 cycle	 regulator	 factors	 expression.	 Indeed,	 MYC	 activates	 transcription	 of	genes	 essential	 for	 cell	 cycle	 progression,	 such	 as	 CDKs,	 cyclins	 and	 E2F1	 (26,	27).	MYC	also	can	indirectly	induce	the	activation	of	complex	cyclin/Cdk	through	the	activation	of	Cdk	activating	kinase	(CAK)	and	Cdc25	phosphatases	(28).	On	the	other	hand,	Myc	can	also	antagonize	antiproliferative	genes,	such	as	p21	(29,	30)	and	p27	(31).	Moreover,	Myc	stimulates	DNA	replication	by	the	upregulation	of	 genes	 encoding	 proteins	 essential	 for	 replication	 initiation	 and	 by	 its	interaction	 with	 the	 pre-replicative	 complex	 and	 localization	 to	 early	 sites	 of	DNA	synthesis.	Rapidly	dividing	 cells	 need	 a	 constant	 flow	of	 nutrients,	 energy	 and	protein	 to	sustain	a	high	rate	of	replication	and	division	and	MYC	promotes	the	metabolic	adaptation	in	tumor,	regulating	mitochondrial	biogenesis,	glucose	and	glutamine	metabolism	(32).	In	addition	to	these	processes,	MYC	amplification	activates	the	expression	 of	 genes	 encoding	 proteins	 involved	 in	 ribosome	 biogenesis	 and	translation	of	mRNAs	and	promotes	mRNA	capping	(33).	MYC	also	increases	the	translational	 capacity	 of	 cells	 through	 the	 activation	 of	 transcription	 by	 RNA	polymerase	 I	 (34,	 35)	 and	 III	 (36),	 which	 increase	 the	 synthesis	 of	 rRNA	 and	tRNA,	 respectively.	 Finally,	 MYC	 cooperates	 with	 mTOR,	 master	 regulator	 of	protein	 synthesis,	 by	 directly	 stimulating	 the	 activity	 of	 factors	 such	 as	 eIF4E,	which	increases	the	efficiency	of	mRNA	to	occupy	ribosomes	(37).	
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1.1.2	Genomic	instability	MYC	 overexpression	 is	 associated	 with	 activation	 of	 DNA	 damage	 response	(DDR)	 (38-40)	and	 increased	genomic	 instability	 (41,	42),	 suggesting	 that	high	levels	of	MYC	expression	 lead	 to	accumulation	of	DNA	damage.	First,	enhanced	mitochondrial	 biogenesis	 and	 cellular	 metabolism	 induced	 by	 MYC	overexpression	 are	 not	 accompanied	 by	 the	 appropriate	 compensatory	mechanism	that	normally	reduces	the	oxygen	free	radicals	(ROS),	exposing	cell	to	a	ROS	accumulation	with	consequent	oxidative	DNA	damage	(43).		Another	potential	source	of	genomic	instability	may	arise	from	the	MYC	ability	to	regulate	the	biology	of	telomeres;	there	is	evidence	that	MYC	activation	leads	to	end-to-end	 chromosomes	 fusion,	 promoting	 breakage-fusion-bridge	 cycles	 and	subsequently	chromosomal	rearrangements	(44).		Aberrant	proliferation	induced	by	oncogenes	disconnects	DNA	replication	events	by	 other	 processes	 that	 normally	 are	 closely	 coordinated	 to	 ensure	 faithful	duplication	 of	 chromosomes.	 This	 anomaly	 results	 in	 a	 phenomenon	 called	"replication	 stress",	 a	 condition	 that	 generates	 aberrant	 DNA	 replication	intermediates	that	induce	a	DNA	damage	response	on	sites	of	active	replication	and	determine	chromosomal	 instability.	MYC	overexpression	is	associated	with	an	increase	of	active	replication	origins	and	premature	origin	firing,	which	could	lead	 to	 the	 physical	 clashing	 of	 the	 replication	 fork	 along	 with	 the	 RNA	polymerase,	causing	replication	fork	collapse	and	DNA	damage	(45).	Myc	 seems	 to	 be	 also	 involved	 in	 the	 regulation	 of	 DNA	 repair.	 Indeed,	 it	 has	been	 demonstrated	 that	 enhanced	 MYC	 expression	 inhibits	 DSB	 repair	 in	 γ-irradiated	cells,	increasing	genomic	instability	(46,	47).		
1.1.3	Tumor	environment	and	metastasis	Myc	 activation	 is	 also	 associated	 with	 global	 changes	 in	 tumor	microenvironment,	which	may	also	contribute	to	tumorigenesis.	Enhanced	MYC	expression	leads	to	release	of	numerous	tumor	associated	cytokines,	chemokines	and	 other	 inflammatory	 mediators	 that	 activate	 inflammatory	 responses	 and	lead	to	alterations	in	immune	surveillance	mechanisms	(48).	MYC	contributes	to	tumor	 vascularization	 by	 the	 induction	 of	 vascular	 endothelial	 growth	 factor	
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(VEGF)	 expression	 (49)	 and	 the	 repression	 of	 thrombospondin-1,	 leading	 to	adjacent	endothelial	cells	to	proliferate	and	form	the	vascular	network	(50).			Myc	 can	 also	 increase	 cancer	 cells	 ability	 to	 metastasize,	 stimulating	 the	expression	 of	 factors	which	 enhance	 tumor	 invasion	 and	 reduce	 cell	 adhesion.	Indeed,	Myc	 activates	 epithelial-to-mesenchymal	 transition	 (EMT)	 through	 the	regulation	of	 a	miRNA,	miR-9,	which	 targets	E-cadherin,	 a	key	mediator	of	 cell	adhesion	 (51,	 52).	MYC	 also	 promotes	 TGFβ-mediated	 activation	 of	 the	 SNAIL	transcription	 factor,	 both	 directly	 and	 indirectly	 though	 a	micro-RNA	 network	involving	a	LIN28B/let-7/HMGA2	pathway	(53).	Similarly,	MYC	represses	N-Myc	Downstream-Regulated	 Gene	 1	 (NDRG1)	 expression	 (54),	 a	 protein	 that	 has	been	widely	implicated	in	promoting	cancer	cell	migration	and	invasion.	Beyond	direct	 transcriptional	 regulation	 of	 EMT-related	 genes,	 MYC	 could	 facilitate	metastasis	by	its	ability	to	promote	a	stem-like	state,	by	blocking	differentiation	pathways	and	enhancing	self-renewal	and	pluripotency	factors	(55,	56).			
1.2	MYC	and	chromatin		In	the	recent	years	has	emerged	the	notion	that	tumors	in	which	MYC	activation	occurred	 appear	 to	 be	 “addicted”	 to	MYC	 high	 levels	 to	 sustain	 the	malignant	state,	 including	 in	 cases	where	MYC	 is	 not	 the	 primary	 oncogenic	 driver	 (57).	Accordingly,	several	reports	suggest	that	suppression	of	MYC	expression	via	RNA	interference,	 short	 hairpin	 and	 antisense	 oligonucleotides,	 in	 a	wide	 variety	 of	MYC-amplified	tumors,	increases	apoptosis	and	differentiation,	and	restores	the	normal	 tissue	 architecture	 (58-60),	 suggesting	 that	 targeting	MYC	activity	may	be	 a	 possible	 therapeutic	 strategy	 in	 MYC-amplified	 cancers.	 However,	 MYC	itself,	 as	 most	 transcription	 factors,	 is	 difficult	 to	 drug.	 Given	 the	 pivotal	involvement	of	chromatin	in	MYC	expression	and	activity,	a	promising	approach	to	circumvent	blocking	MYC	is	directly	targeting	chromatin	modifiers	that	drive	MYC-dependent	transcription.			
1.2.1	MYC	proteins	and	histone	acetylation	The	histone	 acetylation	 acts	 on	 transcriptional	 regulation	 through	 at	 least	 two	
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mechanisms:	 while	 on	 the	 one	 hand	 promotes	 the	 opening	 of	 chromatin	structure,	 on	 the	 other	 it	 generates	 binding	 sites	 for	 specific	 protein-protein	interaction	that	recruit	specific	acetylation-dependent	chromatin	reader,	such	as	the	acetyl	lysine-binding	bromodomain.	MYC-mediated	 transcription	 is	 correlated	 to	a	plethora	of	acetylation	events	at	target	 gene	 loci,	 mediated	 by	 a	 large	 number	 of	 histone	 acetyltransferases	(HATs)	 and	 HAT-containing	 complexes	 including	 GCN5/PCAF,	 Tip60,	 and	p300/CBP,	 as	 well	 as	 the	 adaptor	 protein	 TRRAP,	 component	 of	 many	 HAT	complexes	(61-63).		Although	less	studied,	control	of	histone	acetylation	has	also	been	implicated	in	transcriptional	 repression	 by	 MYC.	 Associations	 have	 been	 reported	 between	MYC	and	histone	deacetylases	(HDACs);	indeed,	MYC	has	been	shown	to	recruit	HDAC-containing	 co-repressor	 complexes	 to	 target	 loci,	 correlating	 with	 a	reduction	in	histone	acetylation	and	repression	of	gene	activity	(64-67).			
1.2.2	MYC	proteins	and	histone	methylation		In	 contrast	 to	 histone	 acetylation,	 the	 role	 that	 histone	 methylation	 plays	 in	regulation	of	gene	expression	by	MYC	seems	to	be	more	intricate.	In	Drosophila	Myc	 has	 been	 found	 to	 inhibit	 the	 activity	 of	 the	 thritorax	 protein	 Lid;	 Lid	belongs	 to	 the	 JARID1	 family,	 that	 acts	 as	 demethylases	 targeting	 MeK4-H3.	Expression	of	dMyc	abrogates	Lid	enzymatic	activity,	blocking	demethylation	of	MeK4-H3	and	maintaining	an	active	chromatin	mark	(68).	MYC	 was	 also	 demonstrated	 to	 repress	 its	 target	 gene	 expression	 via	 direct	interaction	with	DNMT3a	and	PRC2	complex	(69,	70).	In	addition,	MYC	has	been	found	 to	 recruit	 the	 H3K4	 demethylase	 LSD1	 to	 target	 genes	 (71).	 	 LSD1	stimulates	MYC	function	trigging	a	transient	demethylation	of	H3K4me2	at	MYC	target	 genes.	 Interestingly,	 in	 this	 case	 demethylation	 determines	 activation	 of	Myc	 target	 genes:	 LSD1	 reaction	 leads	 to	 the	production	of	hydrogen	peroxide	that	locally	induces	the	modification	of	guanines	in	8-oxodG,	which	recruits	DNA	damage	repair	factors	OGG1	and	Ape1	to	stimulate	transcription.	These	findings	give	rise	to	the	interest	on	how	LSD1/MYC	complex	transcriptional	activity	could	be	exploited	in	the	context	of	particular	types	of	MYC-driven	cancers	(71).		
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1.3	LSD1	
	LSD1/KDM1A	is	an	amine	oxidase	that	catalyzes	lysine	demethylation	in	a	FAD-dependent	 reaction	 (72,	 73).	 LSD1	 removes	mono-	 and	 dimethyl	 groups	 from	lysine	 4	 and	 lysine	 9	 of	 histone	H3.	 In	 this	 reaction,	 FAD	 oxidizes	 the	methyl-lysine	generating	an	imine	intermediate	that	is	subsequently	hydrolyzed	to	form	unmodified	 lysine	 and	 formaldehyde	 while	 the	 reduced	 FAD	 is	 oxidized	 by	molecular	oxygen,	forming	hydrogen	peroxide	as	a	by-product.		LSD1	 is	 highly	 conserved	 and	 contains	 three	 protein	 domains:	 an	 N-terminal	SWIRM	 (Swi3p/Rsc8p/Moira)	 structural	 domain,	 a	 tower	 domain	 and	 a	 C-terminal	 amine	 oxidase	 (AO)	 domain.	 The	 SWIRM	and	AO	domains	 interact	 to	form	a	core	structure	that	binds	FAD	not-covalently	and	serves	as	the	enzymatic	domain;	 the	 tower	 domain	 provides	 a	 surface	 platform	 for	 interaction	 with	partners	(74).	LSD1	 associates	 with	 different	 complexes.	 It	 was	 initially	 described	 as	 co-repressor	of	CoREST	(75),	but	has	been	 found	 to	have	a	 role	 in	 transcriptional	activation	 as	 exemplified	 by	 MYC	 induced	 transcription	 mechanism	 described	above.	LSD1	is	also	part	of	a	nucleosome	remodeling	and	deacetylation	complex,	NuRD	(76).		In	 addition	 to	 its	 direct	 activity	 on	 chromatin	 structure,	 LSD1	 also	 regulates	global	 or	 specific	 gene	 expression	 patterns	 through	 demethylation	 of	 non-histone	 targets,	 such	 as	Dnmt1,	 the	major	 enzyme	 responsible	 for	maintaining	DNA	methylation	during	DNA	replication	(77).		LSD1	 also	 inhibits	 DNA	 damage-induced	 cell	 death,	 through	 the	 specific	demethylation	of	p53,	which	blocks	the	interaction	between	p53	and	53BP1,	and	then	the	ability	of	p53	in	promoting	apoptosis	(78).	In	 addition,	 several	 reports	 strongly	 indicate	 that	LSD1	 is	 critically	 involved	 in	several	cell	types	differentiation	and	in	the	epithelial-to-mesenchymal	transition	(79,	80).	LSD1	physically	associates	with	Snail	and	is	recruited	to	epithelial	gene	promoters	 in	 a-Snail	 mediated	 manner,	 with	 consequently	 repression	 of	transcription	 via	 H3K4	 demethylation	 (81,	 82);	 moreover,	 LSD1	 is	 over-expressed	 in	 several	 cancers,	 such	 as	 prostate	 (83),	 bladder	 (84),	
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neuroblastomas	 (85),	 lung	 cancers	 sarcomas	 and	 hepatocarcinomas	 (86).	Considering	 the	 association	 between	 high	 levels	 of	 LSD1	 and	 tumorigenesis,	LSD1	has	been	proposed	as	epigenetic	drugs	target	in	cancer.	
	
1.3.1	MYCN/LSD1	complex	in	neuroblastoma	Neuroblastoma	 is	 the	 most	 common	 extra	 cranial	 solid	 tumour	 of	 infancy.	Neuroblastomas	are	tumours	of	the	sympathetic	nervous	system	and	may	occur	anywhere	along	the	sympathetic	ganglia	(87).	Although	an	excellent	prognosis	 in	patients	with	 low	and	intermediate	risk	has	been	registered	after	cure,	the	outcome	remains	very	poor	for	relapsed	high-risk	disease.	 One	 of	 the	 most	 important	 biological	 markers	 is	 MYCN	 oncogene	amplification,	which	occurs	 in	approximately	25%	of	cases	and	correlated	with	poor	prognosis	and	advanced	stages	of	disease	(89,	90).		In	2009	Schulte	and	co-workers	addressed	the	functional	significance	of	LSD1	in	neuroblastoma	 (85).	 They	 demonstrated	 that	 LSD1	 expression	 correlated	with	adverse	outcome	and	is	involved	in	maintaining	the	undifferentiated,	malignant	phenotype	 of	 neuroblastoma	 cells,	 highlighting	 its	 central	 role	 in	 the	pathogenesis	of	the	malignancy.		LSD1	targeting	resulted	in	growth	inhibition	of	neuroblastoma	 cells	 in	 vitro	 and	 reduced	 neuroblastoma	 xenograft	 growth	 in	vivo.		Noteworthy,	 Prof.	 Majello	 laboratory	 has	 recently	 shown	 that	 LSD1	 interacts	with	MYCN	and	cooperates	in	repression	of	tumor	suppressor	genes	involved	in	MYCN-driven	 oncogenesis	 in	 Neuroblastoma	 (91).	 They	 reported	 that	 MYCN	interacts	and	 recruits	LSD1	on	 its	 target	genes.	LSD1	can	 form	a	 complex	with	MYCN	and	this	complex	controls	transcription	of	genes	such	as	p21	and	clusterin	(CLU).	 	 Inhibition	of	LSD1	causes	reactivation	of	p21,	CLU	and,	plausibly,	other	potential	 tumor	 suppressor	 genes	 involved	 in	 MYCN-driven	 oncogenesis	 with	therapeutic	 effects,	 suggesting	 that	 LSD1	 inhibition	 could	 be	 therapeutically	used,	alone	or	in	combination	with	other	therapeutic	tools,	to	counteract	MYCN-amplified	neuroblastomas.	
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CHAPTER	2	
MYC	IMPAIRS	RESOLUTION	OF	SITE-SPECIFIC	DNA	DOUBLE-STRAND	
BREAKS	REPAIR	
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Although  it  is established  that when  overexpressed,  the  MYC  family  proteins  can  cause  DNA  double-
stand  breaks  (DSBs)  and  genome  instability,  the  mechanisms  involved  remain  unclear.  MYC  induced
genetic  instability  may  result  from  increased  DNA  damage  and/or  reduced  DNA  repair.  Here  we  show
that  when  overexpressed,  MYC  proteins  induce  a sustained  DNA  damage  response  (DDR)  and  reduce
the  wave  of  DSBs  repair.  We  used  a cell-based  DSBs  system  whereby,  upon  induction  of  an  inducible
restriction  enzyme  AsiSI,  hundreds  of  site-specific  DSBs  are  generated  across  the  genome  to  investigate
the  role  of  MYC  proteins  on DSB.  We  found  that high  levels  of MYC  do not  block  accumulation  of  !H2AX
at  AsiSI  sites,  but delay  its  clearance,  indicating  an  inefficient  repair,  while  the  initial  recognition  of  DNA
damage  is  largely  unaffected.  Repair  of both  homologous  and  nonhomologous  repair-prone  segments,
characterized  by high  or  low  levels  of  recruited  RAD51,  respectively,  was  delayed.  Collectively,  these  data
indicate that  high  levels  of  MYC  proteins  delay  the resolution  of  DNA  lesions  engineered  to  occur  in cell
cultures.
©  2015  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Activated oncogenes generally associate with the induction
of DNA damage response (DDR) [1,2]. This phenomenon named
oncogene induced DNA damage (OID) is exemplified by the c-
MYC proto-oncogene. The Myc  proteins (MYC, MYCN and MYCL
in human) are basic helix-loop-helix leucine zipper transcrip-
tion factors driving a wide range of cellular responses depending
on the cellular context. In most human cancers MYC expression
is deregulated and/or significantly increased [3,4]. It has been
clearly demonstrated that supraphysiological levels of MYC  play
a causative role in the onset and progression of many types of
cancers. In addition to its canonical role in transcription, MYC
overexpression in mammalian cells increases genomic instability
[5,6]. Although it is not clear what type of physical alterations
are induced at the DNA level, recent observations propose that at
least two types of DNA damage can be associated with MYC. First,
MYC  overexpression in mammalian cells results in loss of chromo-
∗ Corresponding author. Tel.: +39 081 7643029.
∗∗ Corresponding author. Tel.: +39 081 679062.
E-mail addresses: lania@unina.it (L. Lania), majello@unina.it (B. Majello).
1 These authors contributed equally to this work.
somal integrity associated with chromosomal aberrations [5–9].
An additional source of MYC-induced DNA damage is replication
stress, a poorly understood perturbation of DNA replication. Repli-
cation stress generates aberrant DNA replication intermediates that
induce the activation of DDR at sites of active DNA replication
[10–12]. Such non-transcriptional Myc  effects are likely crucial to
its role in tumorigenesis. However, in both cases the molecular
mechanisms involved remain unclear.
It is likely that MYC-induced genomic abnormalities might be
generated by defects in the repair of double-strand-breaks (DSB).
DSBs are one of the most challenging forms of DNA damage, which
in turn if not correctly repaired, can trigger the onset and pro-
gression of cancer cells. A number of studies have been focused
on DNA-damage response (DDR) mechanisms induced by chemi-
cal compounds or radiations. A limitation of this approach is that
the sites of DNA damage within the genome occur random and
therefore differ from cell to cell, precluding efforts to determine
co-association at specific DSBs. To overcome such limitations sev-
eral systems have been developed that rely on inducible restriction
enzymes capable to generate unambiguously positioned sequence-
specific DSBs. However, sequence-specific DSB-inducible systems
that induce either a single DSB (HO, I-SceI and FokI systems)
[13,14] or several DSBs in ribosomal DNA (I-PpoI system) [15] ham-
per the comparison of DSB repair occurring at different locations.
http://dx.doi.org/10.1016/j.mrfmmm.2015.02.005
0027-5107/© 2015 Elsevier B.V. All rights reserved.
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Recently, stable human cell lines have been developed that express
the 8-bp restriction enzyme (AsiSI) fused to a modified estrogen
receptor ligand binding domain that induces nuclear localiza-
tion of the enzyme after administration with 4-hydroxytamoxifen
(4OHT) causing the rapid and reproducible induction of about 150
sequence-specific DSBs across the genome [16–19]. This system
offers the opportunity to study the wave of repair events in a
defined and reproducible manner.
Using defined cell systems in which site-specific DSBs were
induced in the presence or absence of overexpressed MYC  pro-
teins, we found here that overexpression of MYC  proteins (MYC
and MYCN) does not block recruitment of H2AX at DSBs whereas
induces a sustained DNA damage response (DDR) and most impor-
tantly reduce the resolution of DNA lesions engineered to occur in
cell cultures.
2. Materials and methods
2.1. Cell culture, transfection and drug treatment
U2OS-AsiSI-ER and SHEP-TET-21/N cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented with
antibiotics, 10% fetal calf serum at 37 ◦C in humidified atmo-
sphere with 5% CO2. The pBABE-HA-AsiSI-ER plasmid was stably
transfected in SHEP-TET-21/N cells using a MicroPorator Digital
Bio Technology, in according to the protocol described in [20]
and selection was performed using 1 "g/ml puromycine for two
weeks. U2OS-AsiSI-ER cells were transiently transfected with a
Flag-Myc expression vector [20] by the polyethylenimine (PEI
25 kDa) method as described [21] with a 6:1 ratio of PEI ("g):total
DNA ("g). Induction of HA-AsiSI-ER chimera was  carried out as
described [22] by treatment with 300 nM 4OHT for 4 h. MYCN
expression under control of the TET-OFF system in double sta-
ble TET-21/N-AsiSI-ER cells was turned off by the addition of
tetracycline 1 "g/ml for 1 week before 4OHT treatment. When indi-
cated, 4OHT-treated cells were washed three times in prewarmed
PBS and further incubated with normal medium for the indicated
times.
2.2. Western blot analysis
Whole-cell extracts were obtained using buffer F (10 mM
Tris–HCl pH 7.5, 150 mM NaCl, 30 mM Na4O7P2, 50 mM NaF, 5 mM
ZnCl2, 0.1 mM Na3VO4, 1% Triton, 0.1 mM PMSF). 50 "g of pro-
tein extracts were loaded and separated by SDS-PAGE and WB
was performed with following antibodies: anti-actinin (H-2, Santa
Cruz, 1:1000), anti-MYCN (B8.4.B, Santa Cruz, 1:1000), anti-c-Myc
(9E10, SantaCruz, 1:500), anti-Phospho-p53 (Ser15) (#9284, Cell
Signaling, 1:1000).
2.3. Immunofluorescence
Immunofluorescence of U2OS-AsiSI-ER and TET-21/N-AsiSI-ER
cells was performed as previously described [22]. Briefly, cells were
fixed in 4% paraformaldehyde in PBS, permeabilized in 0.1% Tri-
ton X-100 in PBS, pre-blocked in 2% BSA–3% NS-PBS for 30 min
at room temperature, and then incubated for 1 h at 37◦ C with
mouse anti-HA (32–6700, Invitrogen, 1:50) and rabbit anti-!H2AX
(Abcam, 1:70) for 30′ at 37 ◦C. Primary antibody were detected
by incubation with Cy3-coniugated anti-mouse or FITC-conjugated
anti-rabbit antibody. Images were acquired using a Nikon Eclipse
TE 2000-U microscope.
2.4. FACS analysis
To analyze the DNA profile cells were treated as indicated, fixed
in methanol at −20 ◦C and stained in hypotonic solution of 0.1% Na-
Citrate, 50 "g/ml propidium iodide, 50 "g/ml RNAse and 0.00125%
NP40 for 30′ at room temperature. Cytofluorimetric acquisition and
analysis were performed on a Becton Dickinson FACScalibur flow
cytometer using FACSDiva, CellQuest Pro and ModFit LT 3.0 soft-
wares.
2.5. Chromatin immunoprecipitation
ChIP experiments with chromatin extracts from U2OS-AsiSI-ER
and TET-21/N-AsiSI-ER cells were performed as described [19]. IPs
materials were analyzed in duplicate by quantitative PCR, using
Syber Green 2X PCR Master Mix  (Applied Biosystem). For qPCRs
3 "l out of 150 "l immunoprecipitated DNA was used. Primer
pairs used to measure NBS1 enrichment were located proximal
to AsiSI site at Chr. 1 (250 bp) and Chr. 6 (180 bp), respectively;
whereas those used to assess !H2AX recruitment were located
at 1200 (Chr1) and 1000 (Chr6) bp from AsiSI site, respectively.
For each assay distal (D) amplicons were used as negative con-
trols, complete list of oligos are presented in Supplementary Table
S1. IP efficiency was calculated as described [19] and presented
as percentage of input. All values represent the average of at
least three independent experiments. The following antibodies
were used: anti-!H2AX (phospho S139, Abcam); anti-p95 NBS1
(Abcam).
3. Results
3.1. AsiSI-dependent DSBs induce DDR activation followed by
efficient wave of repair
Following DSBs detection DDR induces cellular DNA-repair
activities with a concomitant transient arrest of cell-cycle progres-
sion (checkpoint function) until DNA damage has been removed.
To analyze the transient arrest of cell-cycle progression follow-
ing induction of DSBs, we  designed an experimental condition
in which proliferating U2OS-AsiSI-ER cells were treated for 4 h
with 4OHT, then cells were allowed to recovery in the absence
of 4OHT, and samples collected at 24, 48 and 72 h for cell-
cycle distribution DDR, activation and accumulation of !H2AX.
As expected, 4OHT induces nuclear translocation of the fused
HA-AsiSI-ER protein in a large number of cells. After 24 h of recov-
ery the nuclear localization of HA-AsiSI-ER was strongly reduced
(Fig. 1A), indicating that HA-AsiSI-ER was  not generating DSBs.
Accordingly with previous studies [14,22], cell cycle analysis shows
that AsiSI-dependent DSBs induced a significant G2  arrest, which
was completely resolved after 72 h of recovery (Fig. 1B), and such
effect was specific to 4OHT treatment since control untreated
cells did not displayed a prominent G2 arrest (Supplementary
Fig. 1). The induction of a robust DDR, measured by accumula-
tion of phosphorylated form of p53-Ser15 (Fig. 1C), was  resolved
by an efficient wave of repair, which reduced p53-Ser15 levels.
To evaluate DSBs formation at AsiSI sites, we performed S139-
phosphorylated histone H2AX (!H2AX) Chip. Following the robust
increase of !H2AX at the AsiSI sites after 4OHT treatment we
found a progressively reduction in time of the !H2AX accumulation
(Fig. 1D).
Collectively, these data indicate that AsiSI-dependent DSBs in
U2OS cells, induces a robust DDR activation, which is followed by
efficient wave of repair leading to a progressive reduction of DDR
at 48 h after DSBs onset.
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Fig. 1. AsiSI-induced DSBs trigger DDR activation followed by efficient wave of repair. (A) U2OS-AsiSI-ER cells were treated for 4 h with 4OHT or vehicle (Untr) and then
released into fresh medium for 24 h (recovery 24 h). Cells were fixed and processed for anti-HA immunofluorescence and DAPI staining. Values on the right side indicate
percentage of nuclear HA positively stained cells. (B) Cell-cycle distribution of U2OS-AsiSI-ER cells, treated as indicated, was measured by FACS analysis; the average values
from  three independent experiments are reported in the table; all standard deviations are <15%. (C) U2OS-AsiSI-ER cells were treated for 4 h with 4OHT or vehicle and then
released into fresh medium for indicated times. Cellular extracts were prepared and stained with anti-phospho-p53. Actinin has been probed as loading control. (D) !H2AX
enrichment was  estimated by ChIP experiments in AsiSI-ER U2OS treated as indicated above. IP materials were analyzed by q-PCR using a set of primers located about 1 kb
away  from the DSB on the indicated chromosomes. The values reported were calculated as percentage of input. The result is an average of three experiments with error bars
showing standard deviation.
3.2. MYC  overexpression affects DSBs repair in U2OS-AsiSI-ER
cells
To investigate the impact of MYC  overexpression in DDR, U2OS-
AsiSI-ER cells were transfected with a Flag-MYC expression vector,
treated 24 h later with 4OHT (4 h) and, collected at 24 h, 48 h and
72 h after treatment. Fig. 2A shows that, overexpression of MYC
interferes with the timing of AsiSI-induced DSBs repair. We  found
that transient arrest of cell proliferation in control cells is resumed
at 48 h after DSBs; in contrast, MYC  expressing cells with induced
DSBs show reduced cell numbers, particularly from 48 to 72 h
suggesting that cell death is occurring (Fig. 2A). Damaged MYC
overexpressing cells are mainly arrested in G2 even 72 h after treat-
ment (Fig. 2C) suggesting that these cells display a longer DDR.
The persistent activation of DDR is indicated by the accumula-
tion of P-p53-Ser15 at 48 h after DSBs (compare lanes 4 and 8 of
Fig. 2D). Conversely, in 4OHT-untreated cells Myc  overexpression
does not induces detectable increase P-p53-Ser15 (compare lanes
1 and 5 of Fig. 2D), while a small induction of !H2AX foci was
found in a fraction of cells (Supplementary Fig. 2). Consequently,
DDR activation is largely due to DSBs induction rather than MYC
overexpression.
DDR cascade begins with the detection of DSBs by the MRN
(MRE11-RAD50-NBS1) complex, which recruits and activates PIKK
kinases (ATM, ATR and DNA-PK) each capable to phosphorylate
H2AX at Ser139 [23–25]. To analyze the efficiency of these steps
detecting DSBs and to monitor the resolution of DNA damage-
associated !H2AX and NBS1 accumulation at defined AsiSI sites
we performed ChIP with !H2AX and NBS1 antibodies. The ChIP
samples were analyzed by quantitative qPCR with probes located
in the proximal (P) and distal (D) positions of the chromosomal
AsiSI site (Fig. 3A and B). As expected, we  found that in control
cells expressing endogenous low levels of MYC  both sites accu-
mulated !H2AX at DSBs that disappeared by 24 h of recovery. In
cells overexpressing MYC  protein the levels of !H2AX and NBS1
recruited to DSBs were largely similar to control cells, while a
persistent accumulation of both !H2AX and NBS1 at DSBs was
found, indicating that high levels of MYC  impairs resolution of DNA
repair. Moreover, cells that cannot resolve the breaks may die.
Because DSBs accumulation of !H2AX occurs within minutes of
the DNA damage event, we determined the timing of recruitment
and resolution of !H2AX in cells exposed to AsiSI-damage for a
short period of time (30′). Fig. 3 panel C, shows that MYC  overex-
pression does not inhibit !H2AX deposition, but its release from
the damaged sites.
Collectively, our data indicate that overexpressed MYC  does
not significantly affect early !H2AX recruitment, but it reduces
the efficiency of repair and the release of the recruited !H2AX
and NBS1from the damaged sites. It is likely that cells that cannot
resolve DSB would eventually die.
3.3. MYCN impairs DSBs repair in Neuroblastoma cells
Because MYC  and MYCN proteins share many similar sequences
and functions we sought to investigate the effects of overexpressed
MYCN in the repair mechanisms of AsiSI-induced DSBs. To this
end, U2OS-AsiSI-ER cells were transfected with the Flag-MYCN
expression vector and after 24 h cells were treated with 4OHT
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Fig. 2. MYC  overexpression affects DSBs repair in U2OS-AsiSI-ER cells. (A–D) U2OS-AsiSI-ER cells were transfected with the Flag-MYC expression vector or empty vector;
after  24 h cells were treated for 4 h with 4OHT or vehicle (Untr), washed three times, and allowed to recover for the indicated times before processing. (A) Direct cell count
time  course analysis was performed in parental U2OS-AsiSI-ER cells (dashed line) and in MYC-overexpressed cells (solid line). Values are expressed as a percentage of seeded
cells  number. All values represent the average of three independent experiments. Error bars indicate SD. (B) MYC  protein levels in transfected U2OS-AsiSI-ER cells were
determined by WB.  (C) Cell-cycle distribution of MYC-overexpressed U2OS-AsiSI-ER cells treated as indicated was measured by FACS analysis; the average values from three
independent experiments are reported in the table; all standard deviations are <15%. (D) Whole cell extracts from control and MYC-transfected U2OS-AsiSI-ER cells were
prepared from 4OHT-treated cells for 4 h with OHT and after recovery (Rec) for the indicated times and probed with anti-phopho-p53 or anti-actinin as loading control.
(4 h) and with additional 24 h (recovery). We  found that MYCN
overexpression induces a persistent accumulation of !H2AX at
AsiSI DSBs, suggesting that like MYC  also MYCN impairs the repair
mechanisms of AsiSI-induced DSBs in U2OS-AsiSI-ER cells (Supple-
mentary Fig. 3). Because MYCN plays a causative role in human
Neuroblastoma, to further analyzed the role of MYCN in DSBs
repair mechanisms, we  constructed an inducible AsiSI-ER derived
Neuroblastoma SHEP-TET-21/N cell line (TET-21/N-AsiSI-ER). The
SHEP-TET-21/N cells express MYCN under control of the TET-
OFF system thus addition of tetracycline strongly reduces MYCN
expression [26]. In the double stable TET-21/N-AsiSI-ER cells, MYCN
can be turned off by the addition of tetracycline, while AsiSI-ER can
be induced by 4OHT treatment. TET-21/N-AsiSI-ER cell populations
grown in the presence or absence of tetracycline were treated with
4OHT for 4 h and the effects were analyzed by indirect immunofluo-
rescence. Exposure to 4OHT of both high and low MYCN expressing
cells, resulted in nuclear accumulation of the AsiSI fusion protein, as
detected by immunofluorescence (Fig. 4A). This was accompanied
by a significant increase in the number of DNA damage !H2AX foci.
To address the role of MYCN overexpression in DDR mechanisms of
site-specific DSBs, TET-21/N-AsiSI-ER cells expressing high or low
MYCN levels were exposed to 4OHT and samples collected after
recovery at 24 h and 48 h, and analyzed for DDR activation and accu-
mulation of !H2AX. A wave of DDR activation as indicated by the
accumulation of P-p53, was  found in both high and low-expressing
MYCN cell populations, with an increase of the relative amounts of
P-p53 at 24 h after recovery (compare lanes 3 and 7 of Fig. 4 panel
B). In parallel, we  performed ChIP with !H2AX antibody to evaluate
the efficiency of DSBs induction and the wave of repair. We  found
that !H2AX accumulated at AsiSI-DSB with a similar efficiency in
either high and low expressing MYCN cells. In low MYCN cells we
found a progressively reduction in time of the !H2AX deposition.
Conversely, MYCN overexpression induces a persistent accumula-
tion of !H2AX, indicating that in analogy with MYC, overexpression
of MYCN delays resolution of DNA damage-associated !H2AX
recruitment.
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Fig. 3. MYC overexpression delays the presence of !H2AX and NBS1 in cells following DSBs induction. Control and MYC-transfected U2OS-AsiSI-ER cells were treated as
described in Fig. 2, and processed for ChIP experiments using anti-!H2AX (A and C) and anti-NBS1 (B) antibodies. !H2AX and NBS1 enrichment was  estimated by q-PCR,
using  probes located in proximal (P) and distal (D) position from the AsiSI-site. Distal amplicon were used as negative control. (C) ChIP analysis with !H2AX of control and
MYC-transfected U2OS-AsiSI-ER cells after a sort pulse of 4OHT treatment (30′) and wave of recovery of 3, 6 and 24 h as indicated. The values reported were calculated as
percentage of input. Error bars indicate SD for three independent experiments.
3.4. MYC  represses both RAD51-bound and RAD51-unbound
DSBs repair
In a recent work from Legube’s laboratory, [19] ChIP-seq analysis
of U2OS-AsiSI-ER chromatin have been used to define and char-
acterize two subsets (containing 20 DSBs each) of RAD51-bound
and RAD51-unbound DSBs on the basis of respective enrichment
of XRCC4 and RAD51 (RAD51/XRCC4 ratio). RAD51 plays a major
role in homologous repair of DSB and the presence of RAD51 at
chromatin sites undergoing DSB has been indicated as a signature
of homologous repair. Specifically, RAD51-rich DSBs are repaired
essentially by HR, while RAD51-depleted are most likely repaired
by NHEJ. To determine if MYC  overexpression interferes with HR-
prone sites, we investigated the timing of !H2AX recruitment
to the RAD51-rich or depleted sites in cells overexpressing MYC.
U2OS-AsiSI-ER cells were transfected with the Flag-MYC expres-
sion vector and after 24 h cells were treated with 4OHT (4 h)
followed by 24 h of recovery (Fig. 5). We  found that recruitment and
resolution of !H2AX of either RAD51-bound or RAD51-unbound
DSBs exhibited a similar accumulation and resolution of !H2AX,
suggesting that MYC  overexpression abnormally delays resolution
of DNA lesions occurring at both DSBs categories.
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Fig. 4. MYCN impairs DSBs repair in Neuroblastoma cells. (A) TET-21/N-AsiSI-ER were grown in presence (Low MYCN) or absence (High MYCN) of tetracycline, treated for
4  h with 4OHT or vehicle (Untr) and co-stained with anti-HA and anti-!H2AX antibodies. DAPI staining of nuclei is shown. (B) Protein extracts from TET-21/N-AsiSI-ER were
prepared after 4 h of treatment with 4OHT or vehicle (Untr) and recovery for the indicated times. Immunoblots were probed with anti-MYCN, anti-Phospho-p53 and anti-
actinin  antibodies as indicated. (C, D) TET-21/N-AsiSI-ER expressing cells Low (C) and High (D) levels of MYCN were treated as above and ChIP experiments were performed
using  anti-!H2AX antibody primers localized in proximal (P and P1) and distal (D) position from the AsiSI-site. Data are from independent experiments with SD (n = 3).
4. Discussion
In this study, by using human cell lines expressing the estro-
gen receptor-inducible AsiSI restriction enzyme (U2OS-AsiSI-ER
and TET-21/N-AsiSI-ER), we have found that overexpression of MYC
proteins (MYC and MYCN) induce a sustained DDR and impair the
wave of DSBs repair at the DNA lesions.
Using a ChIP approach we have addressed the influence of MYC
protein levels on the DSBs recruitment and resolution of repair
factors. One of the key events of DNA lesion repair is the phos-
phorylation and recruitment of H2AX at DSBs. There are three PIKK
kinases (ATM, ATR and DNA-PK) each capable to phosphorylate
H2AX at Ser139 [23–26], a modification that occurs shortly after
DNA damage event. !H2AX spreads up to a megabase from the
site of the break [16], and it is thought to provide a platform for
recruitment and retention of additional DDR proteins forming a
focus that is detectable by immunofluorescence. We  have found
that MYC  modestly inhibits deposition of !H2AX and NBS1, a com-
ponent of the MRN  complex (MRE11-RAD50-NBS1). However, such
effect was not observed in Neuroblastoma cells [26] suggesting
that the modest inhibition of !H2AX and NBS1 recruitment seen
in U2OS cells is likely cell-specific. Hence, MYC  does not prevent
appropriate !H2AX formation, suggesting that at least the initial
recognition steps of DSBs are largely unharmed. In sharp contrast,
overexpressed MYC  or MYCN protein induced a persistent accu-
mulation of !H2AX and NBS1 at DSBs, thus, affecting resolution of
DNA damage-associated !H2AX recruitment. Based on our data it
appears that MYC  most likely indirectly affects gene products that
mediate DSBs repair processes rather than directly interfere with
the initial steps of the DNA repair response.
DSBs are repaired mainly by two  types of mechanisms:
nonhomologous end-joining (NHEJ) and homologous recombina-
tion (HR). Recently, ChIP-seq analysis of induced AsiSI-DSBs in
U2OS-AsiSI-ER cells with antibodies for RAD51 and XRCC4, core
components of the HR and NHEJ machineries allowed the identi-
fication of an HR-prone subset that recruit the HR protein RAD51
[19]. Using specific probes for these DSBs categories we found that
MYC  impairs repair of both RAD1-bound as well as RAD1-unbound
DSBs suggesting that either HR or NHEJ repair mechanisms are
negatively regulated by MYC.
The mechanism by which MYC  impairs DSBs repair is not clear.
MYC does not block activation of H2AX; thus, initial recogni-
tion of DNA damage is unlikely to be affected. However, MYC
overexpression activates DDR that results in cell cycle arrest, senes-
cence, or apoptosis [7–9,27,28]. A well described model linking
MYC  overexpression to p53 pathway is via transcription induc-
tion of ARF by MYC, which in turn inhibits MDM2  (a key negative
regulator of p53)[29]. However, in U2OS the ARF locus (p14
and 16) expression is undetectable, hence the sustained activa-
tion of p53 mainly relays on MYC-dependent inhibition of DSBs
repair.
DNA repair pathways involve a large number of factors, thus
MYC  may affects proper DNA repair at several different layers.
Intriguingly, MYC  binds to and regulates expression of several
repair factors such as TIP60, MRE11, ATM. On the other end, it has
been shown that MYC  can interact with several DNA  repair factors
12 S. Ambrosio et al. / Mutation Research 774 (2015) 6–13
High MYC 
4OHT 
24 h Rec 
- + + 
- + + 
- + + 
- + + 
- + + 
- + + 
DSB-1 DSB-6 DSB-I DSB-3 DSB-VI DSB-V 
%
 In
pu
t 
0
0,04
0,08
0,2
0,12
0,16
Low MYC 
4OHT 
24 h Rec 
- + + 
- + + 
- + + 
- + + 
- + + 
- + + 
DSB-1 DSB-6 DSB-I DSB-3 DSB-VI DSB-V 
%
 In
pu
t 
0
0,04
0,08
0,2
0,12
0,16
Fig. 5. MYC  represses both RAD51-bound and RAD51-unbound DSBs. ChIP was carried out using anti-!H2AX antibody in untransfected (−MYC) and Flag-Myc (+MYC)
transfected U2OS-AsiSI-ER cells treated as described in Fig. 2. !H2AX enrichment was analyzed by qPCR, using probes located at 800 bp from selected DSBs (DSBs-1, -3 and
-6  are RAD51-unbound; DSBs-I, -V and -VI are RAD51-bound). Oligo primers were as described [19]. The values reported were calculated as percentage of input. Error bars
indicate  SD (n = 3).
such as TIP60, DNA-PK and MRE11 [31,32]; however the functional
consequences of such interactions remain elusive.
Recent studies have clearly highlighted the role of chromatin
structure in the control of DBSs repair mechanisms [30–36].
MYC  binds thousands of genomic loci inducing robust chromatin
changes. Using the same cell line employed in this work (U2OS
cells), ChIP-sequencing identified 20,014 peaks for endogenous
low-levels of MYC, while in cells overexpression MYC  the num-
ber of MYC-bound loci increase to 45,645, of which 14,903 were
localized in promoters [37]. It is possible that high levels of MYC
protein may  influence DNA repair by altering chromatin structure
surrounding DSBs.
In conclusion, we have reported here for the first time that MYC
does not affect the initial stages of DNA repair, but it inhibits res-
olution of DSBs. We  suggest that the use of dedicated cell lines in
which inducible specific DSBs may  occur, could be instrumental for
future characterization of the molecular events underlying MYC’s
ability to suppress DNA repair.
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ABSTRACT
DNA double strand breaks (DSBs) elicit prompt activation of DNA damage 
response (DDR), which arrests cell-cycle either in G1/S or G2/M in order to avoid 
entering S and M phase with damaged DNAs. Since mammalian tissues contain both 
proliferating and quiescent cells, there might be fundamental difference in DDR 
between proliferating and quiescent cells (or G0-arrested). To investigate these 
differences, we studied recruitment of DSB repair factors and resolution of DNA 
lesions induced at site-specific DSBs in asynchronously proliferating, G0-, or G1-
arrested cells. Strikingly, DSBs occurring in G0 quiescent cells are not repaired and 
maintain a sustained activation of the p53-pathway. Conversely, re-entry into cell 
cycle of damaged G0-arrested cells, occurs with a delayed clearance of DNA repair 
factors initially recruited to DSBs, indicating an inefficient repair when compared to 
DSBs induced in asynchronously proliferating or G1-synchronized cells. Moreover, we 
found that initial recognition of DSBs and assembly of DSB factors is largely similar 
in asynchronously proliferating, G0-, or G1-synchronized cells. Our study thereby 
demonstrates that repair and resolution of DSBs is strongly dependent on the cell-
cycle state.
INTRODUCTION
Eukaryotic genome is constantly being challenged 
by various endogenous and exogenous insults. These 
damaging events include crosslinks, base modifications, 
base mismatches, stalled replication forks, single-strand 
breaks (SSBs), and particularly dangerous double-strand 
breaks (DSBs). To deal with such dangerous insults, 
eukaryotes possess an array of distinct pathways to 
monitor and repair damaged DNA.
The initial phases of DSB recognition and 
recruitment of repair factors are now quite elucidated. 
Following DSB the MRE11/RAD50/NBS1 complex 
senses a DSB within seconds and then activates 
PI3K-like kinases ATM (ataxia-telangiectasia mutated) 
protein kinase, a large Ser/Thr kinase of the PI3K-
like kinase family, which also includes DNA-PKcs 
(DNA-dependent protein kinase catalytic subunit), and 
ATR [1–4]. ATM then phosphorylates histone H2AX 
on Ser139 (named γH2AX when phosphorylated) in 
DSB adjacent chromatin. The primary function of 
γH2AX is to recruit its decoder, MDC1 (mediator of 
DNA damage checkpoint protein 1), which recognizes 
the phosphorylated Ser139 epitope on γH2AX. γH2AX-
bound MDC1 recruits in turn more MRN complexes (via 
an interaction with NBS1) and thus initiates a positive 
ATM feedback loop that leads to the amplification of 
the γH2A.X chromatin domain [5–8]. Concomitant with 
the assembly of DNA repair factors at DNA lesion, DSB 
response activates DNA-damage checkpoints (DDR), 
and diffusible signaling events that can arrest cell cycle 
progression either in G1 or G2 to allow for DNA repair 
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and prevent transmission of damaged DNA to daughter 
cells (9,10). However, it must be emphasized that the 
tissue and organs of mammals consist of different cell 
types, including dividing, non-dividing and stem cells 
that coexist in several tissues, in separate yet adjoining 
locations [11]. Normal mammalian cells possess unique 
regulatory mechanisms to shift from a quiescent state to a 
proliferative state and dysregulation of these mechanisms 
might result in malignant transformation. Cellular 
quiescence and the capacity to enter the proliferation cycle 
are critical for maintaining tissue homeostasis [12, 13].
During interphase, DSB can be repaired in a cell-
cycle dependent manner by two major mechanisms: 
classical non-homologous end joining (NHEJ, during G1 
phase) or homologous recombination repair (HR, mainly 
in S-G2 phases) [14–16]. Several studies unveiled cell 
cycle-regulated circuits that govern DSB repair pathway 
choice to ensure that NHEJ dominates in G1 and HR is 
favored from S phase onward [17–21]. Although cell-cycle 
phase contributes to this choice, these pathways coexist 
in S- and G2-phases, thus implying that other factors 
participate in this decision such as chromatin context in 
which DSB occurs [22–24].
It is now well established that DDR differs in 
mitotic and interphase cells [25, 26]. It has been shown 
that DDR is dampened during mitosis. Cells have evolved 
mechanisms to suppress DSB repair during M phase to 
prevent genome instability [27, 28]. Clearly, different 
molecular mechanisms involved in DNA repair occurring 
at specific cell cycle phases have been evolved, and 
recruitment of DSB repair factors and resolution of DNA 
lesions induced at site-specific DSBs occurring during 
different phases of the cell cycle could be instrumental to 
investigate these differences.
To avoid potential anomalies associated with 
transformed cell lines, we produced a cellular system 
suitable to the induction of specific DSBs in the 
immortalized non-tumorigenic epithelial cell line 
MCF10A. We stable transfected these cells with a well-
documented AsISI-inducible vector that express the 
8-base restriction endonuclease AsiSI fused to a modified 
oestrogen receptor ligand binding domain that induces 
nuclear localization of the enzyme after administration 
with 4hydroxytamoxifen (4OHT) causing the rapid and 
reproducible induction of about 150 sequence-specific 
DSBs across the genome [23, 29–31]. This system 
(MCF10A-AsiSI-ER) offers the opportunity to study the 
wave of repair events occurring at defined stages of the 
cell cycle in a defined and reproducible manner.
We found the DSBs occurring in G0 quiescent cells 
are irreparable with a sustained activation of the p53-
pathway. Conversely, re-entry into cell cycle of damaged 
G0-arrested cells shows a delayed clearance of recruited 
DNA repair factors bound at DSBs, indicating inefficient 
repair. This study thereby demonstrates the crucial role of 
cell cycle phases in repair and resolution of DSBs.
RESULTS
Induction of specific DSBs in non-tumorigenic 
epithelial MCF10A cells
To investigate DSB damage and avoid potential 
anomalies associated with transformed cell lines, we 
sought to produce a cellular system suitable to the 
induction of specific DSBs in the immortalized non-
tumorigenic epithelial cell line MCF10A. To this 
end MCF10A cells were transduced with a retroviral 
vector expressing the fusion protein between the 
HA-tagged AsiSI restriction enzyme and a modified 
hormone-binding domain from the estrogen receptor. 
Following drug selection, one cell clone was isolated 
(named MCF10-AsiSIER) and the effects of 4OHT 
administration at different time points were analyzed 
by indirect immunofluorescence. Exposure to 4OHT for 
2 hours resulted in nuclear accumulation of the AsiSI 
fusion protein, as detected by anti-HA-tag antibodies 
(Figure 1A). This was accompanied by a significant 
increase in the number of DNA damaged foci, 
visualized with antibodies against S139-phosphorylated 
histone γH2AX (Figure 1B). 4OHT was removed 
from the medium after 2 hours and cells cultivated 
for additional 4 and 8 hours (Recovery). As shown 
in Figure 1A, the nuclear localization of HA-AsiSI-
ER was strongly reduced after 4 hours of recovery, 
and barely detectable after 8 hours, indicating that the 
HA-AsiSI-ER endonuclease was not active anymore 
(Figure 1A). The generation of the MCF10-AsiER 
clone enabled us to investigate recruitment of DNA 
damaging factors at specific DSBs by using ChIP-based 
approaches. As initial test we focused on the AsiSI sites 
on chromosomes 1 and 6 at which γH2AX recruitment 
had been observed and documented by treatment of 
U2OS AsiSI cells [29]. We conducted ChIP assays with 
antibodies against some of the DDR components and 
we used sequences of published primer sets (listed in 
Table S2). As illustrated in Figure 1C, we observed 
increased enrichment of γH2AX, NBS1, and XRCC4 at 
the Chr1 and Chr6 AsiSI sites. These results confirm that 
recruitment of these factors in MCF10-AsiER paralleled 
the effects observed in previously described clonal 
population of U2OS-AsiER cells.
DSBs induce DDR activation followed by 
efficient repair in MCF10A proliferating cells
Following the generation of DSBs, DDR promotes 
cellular DNA-repair activities with a concomitant transient 
arrest of cell-cycle progression (checkpoint function) until 
DNA damage has been removed. To analyze the transient 
arrest of cell-cycle progression following induction of 
DSBs, proliferating MCF10-AsiSIER cells were treated 
for 2 hours with 4OHT and then allowed to recover in 
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the absence of 4OHT for 24, 48 and 72 hours. Samples 
were analyzed for cell-cycle distribution, DDR activation, 
and ChIP accumulation of γH2AX and NBS1 at specific 
AsiSI sites. Cell cycle analysis showed that AsiSI-
dependent DSBs induced a significant G2 arrest, which 
was completely resolved after 72hr of Recovery (Figure 
2A). As shown in Figure 2B, p53-Ser15 phosphorylation 
increased after 4OHT treatment and its levels decreased 3 
days after the removal of the DNA damage insult.
DDR cascade begins with the detection of DSBs 
by the MRN (MRE11-RAD50-NBS1) complex, which 
recruits and activates different PIKK kinases (ATM, ATR 
and DNA-PK), each capable to phosphorylate H2AX at 
Ser139 [3–5]. To analyze the efficiency of these steps 
detecting DSBs and to monitor the resolution of DNA 
damage-associated γH2AX and NBS1 accumulation at 
defined AsiSI sites we performed ChIP with anti-γH2AX 
and -NBS1 antibodies. Following the robust increase of 
γH2AX and NBS1 signals at the AsiSI sites after 4OHT 
treatment, we observed their progressive reduction within 
24 hours (Figure 2C and Supplementary Figure 1).
Collectively, these data indicate that induction 
of DSBs in asynchronously proliferating MCF10 cells 
promotes a robust DDR activation, which is followed 
by an efficient wave of repair leading to a progressive 
reduction of DDR after DSBs onset.
DSBs in quiescent MFC10 cells are irreparable 
and cause a sustained activation of the p53-
pathway
In mammalian tissues, cells are in both 
proliferating and quiescent states depending on the 
given tissue and these two different populations may 
also coexist in several tissues, in separate yet adjoining 
locations. However, comparative study of these two 
distinct cell cycle states regarding the capability to sense 
and resolve DNA DSB damaging insults has been poorly 
characterized. To address this issue and investigate if 
quiescent or proliferating cells equally sense and resolve 
DSBs over time, we took advantage of the MCF10AsIER 
cells which can be induced in a quiescent state by 
growth factors deprivation for 2 days (referred to as G0 
cells). G0 cells were then treated or not with 4OHT for 2 
hours to induce DSBs. The efficiency of DSB induction 
at each AsiSI site was measured in these two conditions 
by ChIP-sequencing of proliferating and G0-arrested 
cells using the anti-γH2AX antibody. Similarly to ChIP 
data already available for U2OS cells [22], γH2AX 
showed a typical pattern with signals encompassing 
the DSBs for 1-2Mb around the AsiSI sites, with the 
typical signal drop occurring exactly at the restricted 
AsiSI sites (Figure 3, and Supplementary Figure 2). 
Figure 1: 4OHT treatment triggers DSBs formation at AsiSI sites in MCF10A. A. MCF10A-AsiSI-ER cells were treated for 
2 h with 4OHT or vehicle (Untr) and then released into fresh medium for 4 and 8 h (Recovery). Cells were fixed and processed for anti-
HA immunofluorescence and DAPI staining. B. MCF10A-AsiSI-ER cells were treated for 2 h with 4OHT and stained with anti-γH2AX 
antibody. DAPI staining of nuclei is shown. C. MCF10A-AsiSI-ER cells were treated as above and ChIP experiments were performed using 
antibodies against γH2AX, NBS1 and XRCC4. Real-time qPCR was done on ChIP materials using primers listed in Supplementary Table 
2. Amplicon far from any AsiSI site was analyzed as negative control. Data are from independent experiments with SD (n = 3).
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Most importantly, we confirmed the results by analyzing 
150 γH2AX peaks and found that γH2AX mapped with 
similar efficiency in both G0 and proliferating cells 
(Figure 3 and Supplementary Figure 2 and Table 3). 
From these observations we assessed that the efficiency 
of DSBs induced in either proliferating or G0-arrested 
cells is largely similar. Next, we followed γH2AX 
and 53BP1 foci formation by immunofluorescence in 
damaged G0-arrested cells. We found that, similarly to 
proliferating cells, G0-arrested cells exposed to 4OHT 
for 2 hours showed a drastic induction of γH2AX 
and 53BP1 foci. However, we found that DSB in G0-
arrested cells were not repaired, with a persistent 
accumulation of γH2AX and 53BP1 foci up to 5 days 
after DSB induction, thus suggesting an impaired repair 
proficiency (Figure 4A). Accordingly, γH2AX ChIP 
data showed a sustained accumulation of γH2AX signal 
at the AsiSI sites (Figure 4B). We cannot exclude that 
DSBs might normally repaired in quiescent cells but fail 
to recover normal chromatin arrangement after repair. 
However, sustained expression of the P-p53-p21 axis 
was observed, suggesting that the DDR p53 pathway 
operates in G0-damaged cell. Interestingly, p21, which 
was present at high levels in quiescent cells, was further 
up-regulated after damage (Figure 4C). Moreover we 
found that damaged G0-arrested cells underwent to 
apoptosis after 3 days of OHT treatment, as documented 
by a robust increase of the cleaved PARP1 protein in 
damaged cells. PARP1 cleavage was not observed in 
vehicle treated undamaged cells (Veh) that could be kept 
in culture up to 10 days (Figure 4D and data not shown).
Next we investigated whether the lack of DNA 
repair efficiency was a consequence of different expression 
levels of DDR genes in G0-arrested cells compared to 
proliferating cells. We comparatively quantified expression 
levels of DDR genes in G0-arrested versus asynchronous 
proliferating cells by qRT-PCR and Western blot analysis. 
As shown in Figure 4E and 4F, G0-arrested cells expressed 
the analyzed DDR factors at comparable levels with 
proliferating cells except for RAD51 and ATR. The low 
expression levels of RAD51 and ATR are consistent with 
their role in G1/S phases. Data obtained showed that 
no significant differences were seen between G1/S and 
asynchronous proliferating cells.
Figure 2: AsiSI-induced DSBs trigger DDR activation followed by efficient wave of repair. A. Cell cycle distribution of 
asynchronously growing MCF10A-AsiSI-ER treated for 2h with 4OHT then released into fresh medium and collected as indicated. DNA 
content of propidium iodide stained cells was determined by flow cytofluorimetry. B. Total cell extracts from proliferating MCF10A-AsiSI 
before and at the indicated times after 4OHT removal were probed with anti-phospho-p53 and normalized for actinin. C. ChIP against 
γH2AX and NBS1 in MCF10A-AsiSI-ER treated for 2h with 4OHT then released into fresh medium, collected as indicated and analyzed 
by qPCR. Data are from independent experiments with SD (n = 3).
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From these findings we concluded that G0-arrested 
cells lack DNA repair proficiency, but retain the capability 
to activate DNA damage response.
Cell-cycle reentry induces a delayed resolution 
of DSBs
Our findings demonstrated that DSB occurring 
in G0-arrested cells are not repaired. We then sought 
to determine whether reentry of G0-damaged cells 
in cell cycle progression might recover DNA repair 
proficiency. First, we monitored the cell cycle re-entry of 
MCF10AsiER cells upon 2 days of starvation. Cells were 
grown in minimal medium for 2 days and then cell cycle 
re-entry was induced by addition of medium containing 
growth factors (hydrocortisone, EGF, insulin, cholera 
toxin). Flow cytometry analysis revealed an increase of 
S phase cells 8 hours after growth factors addition, with a 
concomitant increase of Ki67 levels compared to starved 
cells; moreover after 24 h, percentages of cell cycle phases 
Figure 3: ChIP-seq analyses in proliferating and G0-arrested MCF10A-AsiSI-ER cells after 4OHT treatment (2 h), 
using anti-γH2AX antibody. Panel A. show the profiles of γH2AX around a selected AsiSI site in both proliferating and G0-arrested 
cells. B. Averaged γH2AX signals of proliferating and G0 cells over a 10-kb windows and centered at the AsiSI site.
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and Ki67 levels were largely similar to growing control 
cells (Figure 5A and 5B).
Damaged G0-arrested cells showed an 
accumulation in G2 phase with a delayed cell-cycle 
re-entry (Figure 5C) with abnormal accumulation on 
both G1 and G2 phases. As shown in Figure 5D, P-p53 
levels increased after DNA damage and accumulation 
of P-p53-Ser15 was detected up to 2 days after DSBs 
followed by a sharp decline at 3 and 5 days after 
recovery, suggesting resolution of induced damage. 
Finally we monitored accumulation of the DNA repair 
factors γH2AX and NBS1 at specific AsiSI sites at 
different time-points after cell-cycle reentry. ChIP 
data demonstrated that γH2AX and NBS1 factors were 
rapidly recruited to the AsiSI sites. However, compared 
to DNA damage in proliferating cells, in damaged G0-
arrested cells we found a persistent accumulation of both 
γH2AX and NBS1 at DSBs (Figure 5E).
Collectively, these data clearly indicate that cell 
cycle re-entry of damaged G0-arrested cells induces 
Figure 4: G0-arrested MCF10-AsiSIER cells lack DNA repair proficiency. A. MCF10A-AsiSIER cells were arrested in G0 
phase through grow factors deprivation for 40h, treated with 4OHT for 2h then kept in medium without grow factors, and analyzed at the 
indicated times after 4OHT removal by immunofluorescence with anti-53BP1 and anti- γH2AX antibodies, respectively. B. Recruitment of 
γH2AX at AsiSI sites (Chr. 1 and 6) was determined by ChIP assays. C. Western blotting was performed using phospho-p53 antibodies and 
p21. D. PARP1 detection of both full-length and cleaved protein fragments; western blotting of G0-arrested MCF10-AsiSI-ER treated with 
4OHT or vehicle, collected at the indicated time points after 4OHT removal. E. DDR factors mRNAs expression analysis of G0-arrested 
MCF10-AsiSI-ER through quantitative RT-PCR. Expression profiles were normalized against proliferating cells. F. Western blot of protein 
extracts of Growing, G0 and G1/S MCF10-AsiSI-ER cells using the indicated antibodies. Actinin has been probed as loading control for 
different blots.
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delayed resolution of DSBs compared to proliferating 
damaged cells; following recruitment of repair factors, 
the progressive reduction in time of accumulation 
of these factors in G0-damaged cells was clearly 
delayed compared to what observed in asynchronously 
proliferating MCF10 cells.
Efficient resolution of DSB induced at G1/S phase
Our findings demonstrated that cell cycle reentry 
of G0-damaged cells allows resolution of DSBs albeit 
with a delayed efficiency compared to proliferating cells, 
suggesting that transition to G1/S phases might be required 
for DSB resolution. We then sought to determine repair 
proficiency in synchronized G1/S-damaged cells. As 
shown by FACS data, 8 hours after cell cycle re-entry, 
G0-arrested MCF10-AsIER cells were synchronized in 
late G1/S phase (Figure 5A). Synchronized cells were 
exposed for 2 hours to 4OHT treatment and then allowed 
to recover: cell samples were collected at different times 
after the 4OHT pulse and analyzed for p53 activation 
and accumulation of DSB factors at specific AsiSI sites. 
G1-damaged cells exhibited a robust p53 activation 
(Figure 6A), and accumulation of the DNA repair factors 
(γH2AX and NBS1) at specific AsiSI sites at different 
time-points following DNA damage. ChIP data showed 
Figure 5: Cell-cycle re-entry induces a delayed resolution of DSBs. In panel A and B. cell cycle profiles and Ki67 levels detected 
by flow cytofluorimetry of G0 MCF10-AsiSI-ER released into fresh medium and collected as indicated. C. Cell cycle distribution of G0-
arrested MCF10A-AsiSI-ER cells treated for 2h with 4OHT, then released into fresh medium and collected as indicated. DNA content of 
propridium iodide stained cells was determined by flow cytofluorimetry. D. Western blotting of MCF10A-AsiSI-ER cells treated as above. 
E. ChIP against γH2AX and NBS1 in MCF10A-AsiSI-ER treated for 2h with 4OHT, then released into fresh medium, collected as indicated 
and analyzed by qPCR. Data are from independent experiments with SD (n = 3).
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that γH2AX and NBS1 were rapidly recruited to the 
AsiSI sites and, most importantly, reduction of these 
DSBs factors followed a kinetics similar to that observed 
in asynchronously proliferating cells (compare Figure 
6B and Figure 2C). The data demonstrated that, unlike 
damaged Go-arrested cells, G1-damaged cells exhibit 
efficient resolution of DSBs.
Because DSBs assembly of DDR repair factors 
occurs within minutes following the DNA damage event, 
we comparatively determined the timing of γH2AX, 
NBS1 and XRCC4 recruitment in cells exposed to AsiSI-
damage for a short period of time (20’) in asynchronously 
proliferating, G0-, or G1-arrested cells. Figure 7 shows 
that early recruitment of these factors is largely similar 
in all the three cell populations analyzed. Thus, the initial 
recognition of DSBs and assembly of DSB factors is 
largely similar regardless of the cell cycle phase during 
which the DSB is produced.
Figure 7: ChIP analysis with γH2AX, NBS1 and XRCC4 antibodies in MFC10AsiSI-ER cells after a short pulse of 
4OHT treatment (20’). The values reported were calculated as percentage of input. Error bars indicate SD for three independent 
experiments.
Figure 6: DSBs induced at G1/S phase. Synchronized cells were exposed for 2 hr to 4OHT and then allowed to recovery for the 
indicted times. A. total cell extracts from G1/S phase MCF10A-AsiSI before and at the indicated times after 4OHT removal were probed 
with anti-phospho-p53 and actinin as loading control. Panel B. ChIP against γH2AX and NBS1 in MCF10-AsiSI-ER analyzed by qPCR. 
Data are from independent experiments with SD (n = 3).
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DISCUSSION
Here we report a comparative study of DSB 
response occurring at specific stages of the cell cycle. We 
generated a human normal non-tumorigenic epithelial 
MCF10A cell line expressing the estrogen receptor-
inducible AsiSI restriction enzyme, which allows the study 
of the wave of repair events occurring during specific 
stages of the cell cycle. We found that DSBs occurring in 
G0 cells are irreparable and G1/S transition is required for 
complete DNA damage resolution. We demonstrated that 
the G0 cells retain a functional DDR but, lacking DNA 
repair competence, they may accumulate DNA damage, 
which could reach critical levels and triggers the apoptotic 
cascade.
In agreement with previous studies in U2OS [22, 
30–33], AsiSI dependent DSBs in proliferating MCF10A 
induce canonical DDR activation, which is followed by 
progressive resolution of DSBs. Conversely, we found 
that DSB induction in G0-arrested cells leads to efficient 
γH2AX and 53BP1 foci formation, but differently from 
asynchronous cells, damage is never repaired. Damaged 
G0-arrested cells show a robust and irreversible activation 
of the phospho-p53/p21 axis, and undergo apoptosis one 
week after DSBs induction. Through ChIP-sequencing we 
found that proliferating and G0 damaged cells showed the 
same number of DSB domains with similar enrichment 
of γH2AX, demonstrating that the efficiency of DSBs 
induced in either proliferating or G0-arrested cells is 
largely similar. Moreover, ChIP experiments revealed 
that in G0 damaged cells the levels of γH2AX, NBS1 
and XRCC4 recruited to DSBs were largely similar to 
synchronous proliferating cells; thus, the cell cycle phase 
does not interfere with the initial steps of DNA damage 
response. However, the persistent accumulation of repair 
factors at DSBs indicates that DNA repair resolution is 
compromised in G0 cells. The inability of Go cells to repair 
damage was not due to altered expression of DDR genes, 
since Go-arrested cells show similar expression levels of 
different repair factors when compared to proliferating 
cells, with the exception of RAD51 expression. Lack of 
RAD51 expression in Go cells is consistent with the notion 
that HR, which relays on RAD51 activity is efficient in S 
and G2 cell cycle phase, but limited in G0/G1 [14–16].
Most notably, we find that cell cycle re-entry of G0 
damaged cells restored DNA repair competence, but led 
to delayed resolution of DSBs compared to proliferating 
cells, suggesting that G0-damaged cells required G1/S 
transition to complete DSBs repair. Accordingly, resolution 
of DSBs induced in synchronized G1/S cells occurred with 
kinetic similar to that observed in proliferating cells.
Here we demonstrated that DDR activation does 
not depend on the phase of the cell cycle in which the 
DSB is generated. Similarly, a recent work reported 
that in IR-exposed fibroblasts, quiescence does not 
affect the DNA damage response, and activation of p53 
and phosphorylation of γH2AX are similar between 
proliferating and quiescent cells [34].
Our data reveal that in G0 most of examined DDR 
factors are expressed at levels comparable to those 
observed in proliferating cells, and NHEJ is the main 
repair pathway since RAD51, a critical component of 
HR, is undetectable in Go. However, the G1/S transition 
is required to complete resolution of DSBs induced 
in G0 cells. A possible explanation is that some DSBs 
induced in G1 are repaired by HR as cells progress to 
S phase [35]. Clearly, different molecular mechanisms 
involved in DNA repair occurring at specific cell 
cycle phases have been evolved, and the DDR differs 
in mitotic and interphase cells. It has been shown that 
DDR is dampened during mitosis. During mitosis DDR 
is inhibited to prevent telomere fusion and entry into 
mitosis in the presence of unrepaired DNA can lead 
to cell death, thus DDR clearly differs in mitotic and 
interphase cells [25–28]
Mammalian tissues and organs of consist of different 
cell types, including dividing, non-dividing and stem cells. 
Terminally differentiated cells are permanently withdrawn 
from the cell cycle and partly resistant to apoptosis [36, 
37]. d'Adda di Fagagna and collaborators showed that 
terminally differentiated astrocytes exhibit radio-resistance 
and strongly attenuated expression of most of DDR genes 
compared to undifferentiated progenitors [38]. It has 
been shown that in IR-exposed quiescent myoblast the 
ATM-p53 axis operates normally, while it is compromised 
in differentiated myotubes [39], indicating that the lack of 
a robust DDR and radio-resistance can be linked to the 
terminal differentiation and irreversible exit from the cell 
cycle. We cannot exclude, however, that differences in 
DNA damage response in cultured G0-arrested cells and in 
terminally differentiated non-proliferating cells are strictly 
cell type-specific and depend on the physiological context.
Our findings also help to dispel the dogma that 
completion of DNA damage repair is the essential 
condition for entry in the next phase of the cell cycle and 
stresses the notion the cell cycle position of a damage cell 
affects the repair competence. Further investigations are 
needed to understand mechanisms that coordinate repair in 
proliferating, quiescent and terminally differentiated cells 
to preserve genome integrity.
MATERIALS AND METHODS
Cell cultures and retroviral infection
MCF10A were cultured in 1:1 mixture 
DMEM-F12 supplemented with 5% horse serum, 
10 µg/ml insulin, 0,5 µg/ml hydrocortisone, 100 ng/
ml cholera enterotoxin, and 20 ng/ml epidermal growth 
factor, and incubated at 37°C in humidified atmosphere 
with 5% CO2. To generate MCF10Asi-ER cells the 
pBABE-HA-AsiSI-ER plasmid was transfected into 
Oncotarget10www.impactjournals.com/oncotarget
293T cells expressing the structural components for 
retrovirus packaging, medium was harvested after 36 h, 
filtered and used to infect MFC10 cells and selection 
performed using 1µg/ml puromycin; single cell clones 
were isolated and analyzed.
Cell cycle synchronization
MCF10A-AsiSI cells were arrested in G0 by 
growth in minimal medium (1:1 mixture DMEM-F12 
supplemented with 5% horse serum) for two days. To 
induce re-entry into cell cycle, the GO arrested cells were 
cultured in complete medium and cell cycle re-entry was 
monitored by flow cytometry analysis and Ki67 content.
Antibodies
The antibodies used for different applications in this 
study are listed in Supplementary Table S1.
Flow cytometry analysis
To analyze the DNA profile, cells were fixed in 
methanol at -20°C and stained in hypotonic solution of 0,1% 
Na-Citrate, 50 μg/ml propidium iodide, 50 μg/ml RNAse 
and 0,00125% NP40 for 30’ at room temperature. For Ki67 
quantification cells were permealyzed with 0,1% Triton 
X-100/PBS, blocked in 5% Bovine Serum Albumin/PBS and 
stained with the primary antibody anti-Ki67; then, cells were 
incubated with the secondary antibody Alexa647 Donkey 
anti-goat (Invitrogen) before propidium iodide staining. 
Cytofluorimetric acquisition and analysis were performed 
on a Becton Dickinson FACScalibur flow cytometer using 
FACSDiva, CellQuest Pro and ModFit LT 3.0 software.
Western blot analysis
Whole-cell extracts were obtained using buffer F (10 
mM TrisHCl pH 7.5, 150 mM NaCl, 30 mM Na4O7P2, 
50 mM NaF, 5 mM ZnCl2, 0.1 mM Na3VO4, 1% Triton, 
0.1mM PMSF). 50 μg of protein extracts were loaded and 
separated by SDS-PAGE and WB was performed with 
indicated antibodies.
Immunofluorescence
Immunofluorescences of MFC10AsiSI-ER cells 
were performed as previously described. Briefly, cells 
were fixed in 4% paraformaldehyde in PBS, permeabilized 
in 0.1% Triton X-100 in PBS, pre-blocked in 2% BSA–
3%NS-PBS for 30 min at room temperature, and then 
incubated for 1 h at 37° C with mouse anti-HA and 
rabbit anti-γH2AX for 30’ at 37°C anti-53BP1. Primary 
antibodies were detected by incubation with Cy3-
coniugated anti-mouse or FITC-conjugated anti-rabbit 
antibody. Images were acquired using a Nikon Eclipse TE 
2000-U microscope.
Chromatin immunoprecipitation assays
ChIP experiments with chromatin extracts from 
MCF10-AsiSIER cells were performed as described 
[32]. IPs materials were analyzed in duplicate by 
quantitative PCR, using Syber Green 2X PCR Master 
Mix (Applied Biosystem). For qPCRs 3 μl out of 150μl 
immunoprecipitated DNA was used. The antibodies are 
listed in Table S1. After reversal of the crosslinks, the 
immunoprecipitated DNA was quantified by qPCR with 
the primer sets described in Table S2. For each ChIP 
assay a control amplicon from Chromosome X (Table 
S2) was used.
Chip-sequencing, mapping and peak analysis
ChIP-seq libraries were prepared from 10 ng of 
ChIP (or Input) DNA with TruSeq ChIP Sample Prep Kit 
(Illumina) according to the manufacturer’s instructions. 
Prior to sequencing, libraries were quantified using 
Quibit (Invitrogen) and quality-controlled using 
Agilent’s Bioanalyzer. 50bp single-end sequencing 
was performed using Illumina HiSeq 2000 platform 
(Genomix4life S.R.L., Baronissi, Salerno, Italy) 
according to standard operating procedures. Alignments 
were performed with BWA [40] to hg18 using default 
parameters. SAMtools [41] and BEDtools [42] were 
used for filtering steps and file formats conversion. 
The peaks were identified from uniquely mapped reads 
without duplicates using MACS and the p-value cutoff 
used for peak detection was 1e-5. DNA Input was used 
as control. UCSC genome browser was used for data 
visualization. To plot data of average profiles around 
DSBs, AsiSI site positions were retrieved from the 
human genome (hg18). ChIP-seq counts were retrieved 
for 10 kb around each of these DSBs and averaged with 
a 200-bp window using a custom R-script [43]. ChIP-
seq data were deposited to NCBI GEO and are available 
under accession number GSE71447
RNA extraction and qRT-PCR quantification
RNA was extracted from MCF10A-AsiSIER 
cells using EuroGold Trifast (EuroClone). cDNA 
was generated using Quantitec Reverse Transcription 
Kit (Qiagen), according to manufacturer’s protocol. 
Quantitative analysis was performed using SYBR Green 
2X PCR Master Mix (Applied Biosystem). Each sample 
was run in triplicate and normalized to the expression 
of housekeeping beta-glucoronidase (GUS) gene as 
previously described [44]. Primers are presented in 
Supplementary Table S2.
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ABSTRACT
Neuroblastoma (NB) with MYCN amplification is a highly aggressive and 
metastatic tumor in children. The high recurrence rate and resistance of NB cells to 
drugs urgently demands a better therapy for this disease. We have recently found that 
MYCN interacts with the lysine-specific demethylase 1 (LSD1), a histone modifier that 
participates in key aspects of gene transcription. In cancer cells, LSD1 contributes to 
the genetic reprogramming that underlies to Epithelial-Mesenchymal Transition (EMT) 
and tumor metastasis. Here, we show that LSD1 affects motility and invasiveness 
of NB cells by modulating the transcription of the metastasis suppressor NDRG1 
(N-Myc Downstream-Regulated Gene 1). At mechanistic level, we found that LSD1 
co-localizes with MYCN at the promoter region of the NDRG1 gene and inhibits its 
expression. Pharmacological inhibition of LSD1 relieves repression of NDRG1 by MYCN 
and affects motility and invasiveness of NB cells. These effects were reversed by 
overexpressing NDRG1. In NB tissues, high levels of LSD1 correlate with low levels of 
NDRG1 and reduced patients survival. Collectively, our findings elucidate a mechanism 
of how MYCN/LSD1 control motility and invasiveness of NB cells through transcription 
regulation of NDRG1 expression and suggest that pharmacological targeting of LSD1 
represents a valuable approach for NB therapy.
INTRODUCTION
Neuroblastoma (NB), a disease of the sympathetic 
nervous system, is the most common solid tumor of 
infancy. Despite significant advances in the treatment of 
pediatric cancer over the past two decades, NB remains 
a highly refractory malignancy, with less than 50% 
5-year survival rates for the majority of patients who 
are diagnosed with high-risk disease. One of the most 
powerful independent prognostic indicators for this disease 
is the amplification of the MYCN oncogene, which occurs 
at high levels in approximately 25% of NBs [1-3]. High-
risk NBs often present hematogenous metastasis indicating 
that MYCN amplification control epithelial-mesenchymal 
transition (EMT) through which NB cells lose homotypic 
adhesion and acquire migratory capacity [4]. High level 
of MYCN expression has a great impact on global gene 
expression. [5]. Despite this richness of information, the 
entire and precise network of interactions that MYCN 
establishes within cancer cells remains elusive. Recently, 
we have demonstrated that MYCN interacts with LSD1/
KDM1A, a monoamine oxidase that function as master 
epigenetic regulator in NB cell lines and that the MYCN/
LSD1 complex is involved either in activation or 
repression of MYCN target genes in NB cell lines [6]. 
Importantly, the inhibition of LSD1 activity reduces 
neuroblastoma cell viability and induces differentiation. 
These findings suggest that LSD1 inhibition may have 
strong therapeutic relevance to counteract MYCN-driven 
oncogenesis. 
                  Research Paper
Oncotarget3855www.impactjournals.com/oncotarget
LSD1 is an amine oxidase that catalyzes lysine 
demethylation in a flavin adenine dinucleotide (FAD)-
dependent oxidative reaction. LSD1 removes mono- 
and dimethyl groups from lysine 4 (H3K4) and lysine 9 
(H3K9) of histone H3, and can also targets non-histone 
proteins such as p53, E2F1, and DNMT1 [7-9]. LSD1 was 
initially described as a cofactor of the REST/CoREST 
complex. Although LSD1 can function as a co-repressor 
of transcription factors as REST, it also has been reported 
to function as a coactivator of specific transcription 
factors by removing H3K9 methylation, suggesting that 
its substrate specificity defines its biological outcome 
[10-12]. LSD1 is overexpressed in a variety of cancers 
and tends to correlate with more aggressive cancers with 
poor prognosis. There is a large body of evidence that 
LSD1 is involved in maintaining the undifferentiated, 
malignant phenotype of neuroblastoma cells and that its 
overexpression correlates with aggressive disease, poor 
differentiation and infaust outcome [13, 14]. 
To address the functional significance of LSD1 
inhibition in NB we performed global transcriptome 
analysis (RNA-seq) in LSD1-deficient NB cells. Analysis 
of differentially expressed gene (DEG) highlighted 
the biological relevance of co-target genes indicating 
that epithelial-mesenchymal transition pathway was 
significantly affected. Among genes positively affected 
by LSD1 inhibition we focused our attention on the 
metastatic tumor suppressor gene N-myc downstream 
regulated1, NDRG1. In fact, we find that NDRG1 is 
inhibited by LSD1. NDRG1 is one of the four members of 
the human NDRG family, and its designation comes from 
its expression being repressed by MYC and MYCN [15, 
16] and its expression is negatively correlated with tumor 
progression in multiple neoplasms. NDRG1 is a potent 
metastatic suppressor that has been shown to restrain 
TGF-ß-induced EMT in prostate and colon cancer cells, 
while its reduction induces EMT [17-22]. Collectively 
these studies demonstrated that NDRG1 functions as a 
metastatic suppressor that inhibits EMT in human cancer 
a key initial step in metastasis. 
We found that LSD1 inhibition suffices to de-
repress NDRG1 expression even in the presence of 
MYCN amplification. Expression of NDRG1 suppresses 
motility and invasiveness of NB cells. In silico studies of 
neuroblastoma tumor samples revealed that low expression 
of NDRG1 was associated with poor survival. Low 
NDRG1 and high LSD1 levels were mutually exclusive in 
MYCN-amplified NB samples, corroborating the in vitro 
results. Taken together, our findings provide a previously 
unidentified model to control of EMT in NB, suggesting 
that LSD1 represents a novel and promising target for 
selective inhibition of cell migration and invasiveness in 
neuroblastoma cells. 
RESULTS
LSD1 depletion selectively affects EMT pathway
LSD1 is highly expressed in undifferentiated 
Neuroblastoma and its high expression correlates with 
adverse outcome [13, 14]. We recently showed that MYCN 
interacts with LSD1 and that the LSD1/MYCN complex 
controls transcription of tumor suppressor genes such 
as p21 and CLU [6]. Moreover LSD1 inhibition results 
in cell growth arrest of cultured NB cells. To address in 
more details the role of LSD1 function in NB cells, we 
performed global transcriptome analysis (RNA-seq) of 
Tet-21/N cells treated with tranylcypromine (TCP) a potent 
inhibitor of LSD1. In parallel, we performed RNA-seq 
from Tet-21/N cells treated with siRNA targeting LSD1 
(LSD1-KD). RNA-seq data from duplicate biological 
replicas were then analyzed for differentially expressed 
gene (DEG). Statistical analysis allows us to screen out 
661 DEGs in TCP sample (log2FC ≥ 1; FDR ≤ 0.1) and 
526 DEGs in LSD1-KD (log2FC ≥ 1; FDR ≤ 0.1). 125 
were commonly present in both treatments (Figure 1A, 
B and Supplementary Table 3). To clarify the biological 
relevance of co-target genes we used Gene set enrichment 
analysis. GSEA revealed that among top scoring pathways 
the gene set of Epithelial-Mesenchymal Transition, EMT, 
was ranked as significantly affected in both TCP and 
LSD1-KD samples (Figure 1C). We quantified expression 
levels of EMT marker genes in TCP treated or LSD1-KD 
Tet-21/N cells versus control cells by qRT-PCR. As shown 
in Figure Supplementary 1, LSD1 inhibition increased the 
levels of the epithelial markers, E-cadherin, occludin and 
desmoplakin, and reduced the expression mesenchymal 
markers, Vimentin and α-SMA, whereas no significant 
differences were detected in N-cadherin expression.
Previous studies have shown that LSD1 is indeed 
involved in the control of EMT, through interaction with 
the SNAG domain of SNAI1, a master EMT regulator 
[23, 24]. Among the several genes that were affected in 
TCP-treated and LSD1-KD cells related to EMT (SAT1, 
PLAUR, TNFRSF12A, RGS4, BDNF, MPP3, NDRG1 
and SGK1) we focused our attention on the MYCN 
regulated gene, the metastasis suppressor gene NDRG1 
(N-myc downstream regulated gene 1). NDRG1 was 
first isolated as a gene up-regulated in N-Myc knockout 
mouse embryos [25] and directly repressed by MYCN 
and c-MYC through binding to the NDRG1 core promoter 
[26]. The metastasis suppressor NDRG1 is negatively 
correlated with tumor progression of several types of 
cancer, and most importantly down-regulation of NDRG1 
expression enhances cell proliferation and invasiveness. 
In contrast, its up-regulation reduces cell proliferation and 
invasiveness [27-29]. 
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Figure 1: A. Venn diagram of the DEG present in both LSD1-knockdown (LSD1-KD) and TCP treatment. B. Gene set of regulated 
genes by TCP treatment and LSD1-KD. C. Gene set enrichment analysis (GESA) plots show enrichment of gene sets regulated by LSD1-
KD and TCP treatment. In each panel, nominal NES and false discovery rates (FDRs) are indicated. D. NDRG1 gene expression was 
analyzed by qRT-PCR, using samples prepared from Tet-21/N cells and treated with TCP or siRNA-LSD1 and siRNA-control as indicated. 
LSD1 protein level in Tet-21/N cells transfected with siRNA-LSD1 or control was determined by western blot. *, statistical significance (P 
< 0.01; Student t test). E. Western blotting of protein extracts from Tet-21/N cells prepared as described in D, using NDRG1 and phospho-
NDRG1 (Thr 346) antibodies. F. NDRG1 silencing using sh-NDRG1 in Tet-21/N cells treated with TCP or vehicle, was assayed by western 
blot. G. Western blotting of protein extract from Tet-21/N treated with vehicle, TCP or 10058-F4 for 48 hrs, using NDRG1 antibody. 
Actinin has been probed as loading control. 
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To validate the role of LSD1 in NDRG1 expression 
we inhibited LSD1 in Tet-21/N cells with TCP or siRNA-
targeted knockdown and measured NDRG1 mRNA and 
protein expression levels. We found that TCP treatment 
or LSD1 silencing stimulates NDRG1 expression 
(Figure 1D and 1E). Previously immunoblotting studies 
revealed that NDRG1 might appear as multiple protein 
bands depending from the cellular context likely due to 
different isoforms and/or post-translational modifications 
such as phosphorylation and glycosylation [27, 30, 31]. 
It has been shown that the signal cascade mTORC2/
serum glucocorticoid induced protein kinase1 (SGK1) 
phosphorylates NDRG1 at T346 and this modification is 
essential to suppress tumor growth [20, 32]. Tet-21/N cells 
treated with TCP or siLSD1 were probed with an antibody 
that specifically recognize NDRG1 phosphorylated 
at T346 demonstrating that LSD1 inhibition induces 
NDRG1 phosphorylation, Figure 1E. Finally shRNA-
targeted NDRG1 knockdown demonstrates specificity of 
NDRG1 bands (Figure 1F). To address the contribution 
of MYC and LSD1 to NDRG1 expression, Tet-21/N cells 
were treated with 10058-F4, a small molecule inhibitor 
of MYC/MAX dimerization [6] that has effect on either 
cMYC then MYCN. Following 10058-F4 treatment we 
found an increase of the 43kDa NDRG1 band, while TCP 
activates the 48kDa (Figure 1G). These findings suggest 
that inhibition of either MYCN or LSD1 de-repress 
NDRG1 expression. However, while MYCN inhibition 
activates NDRG1, LSD1-KD also induces NDRG1 
phosphorylation.
MYCN and LSD1 co-localize at NDRG1 promoter 
and repress its expression
To determine whether LSD1 is directly involved in 
transcriptional control of NDRG1 we inhibited LSD1 in 
Tet-21/N cells with TCP or with siRNA against LSD1 and 
assessed the relative binding of MYCN and LSD1 to the 
NDRG1 gene by chromatin immune-precipitation (ChIP) 
assays. The immunoprecipitated chromatin samples 
were subjected to qPCR using primers corresponding to 
the transcriptional start site (TSS) of the NDRG1 gene, 
Figure 2A. As shown in Figure 2B and 2C, MYCN and 
LSD1 were both recruited selectively at the transcriptional 
start site (TSS) of the NDRG1 gene but not at distal sites 
(-10kb), indicating that the MYCN/LSD1 complex binds 
to the NDRG1 promoter. We find also that MYCN binding 
was unaffected by TCP or LSD1 depletion implying 
that MYCN binding does not require LSD1 while, in 
contrast, LSD1 binding was reduced in TCP-treated 
and LSD1-KD samples, suggesting that the binding of 
LSD1 require the catalytic activity of the enzyme. Next, 
we monitored the histone modifications occurring at 
NDRG1 promoter (Figure 2D, 2E). Depletion of LSD1 
enhances H3-acetylation whereas it reduces the repressive 
mark H3K27me3, consistent with the induction of 
NDRG1 expression in these cells. Overall, our findings 
demonstrate that: 1) both LSD1 and MYCN bare recruited 
to the NDRG1 promoter chromatin to repress NDRG1 
expression; 2) LSD1 inhibition is sufficient to relieve 
MYCN-driven NDRG1 repression.
Effects of TCP and SP2509 inhibitors on LSD1/
MYCN-mediated regulation of NDRG1
During last years several small molecular inhibitors 
of LSD1 based on different molecular mechanisms have 
been developed [33]. SP2509 is a reversible inhibitor 
of LSD1 and differently from TCP does not target the 
catalytic activity of the enzyme. SP2509 attenuates the 
binding of LSD1 to CoREST and it has been found to 
be effective in inhibition of cultured and primary AML 
blasts [34]. To further substantiate the role of LSD1 in 
the suppression of NDRG1 we analyzed the effects of 
treatment of NB cells on NDRG1 expression by treatment 
with this different LSD1 inhibitor. As shown in Figure 3A, 
SP2509 treatment enhances NDRG1 mRNA expression 
and increases the NDRG1 48kDa protein levels in a dose 
dependent manner. Thus, both TCP and SP2509 enhance 
NDRG1 expression albeit these drugs inhibit LSD1 
through different mechanisms. Because LSD1/MYCN 
negatively controls NDRG1 transcription we assessed 
whether TCP or SP2509 may interfere with the LSD1/
MYCN interaction. To this end, HEK293T cells co-
transfected with expression vectors encoding LSD1 and 
MYCN were exposed to TCP and the complex between 
MYCN and LSD1 was analyzed by immunoprecipitation. 
As shown in Figure 3B, LSD1 and MYCN readily interact 
in the absence of TCP but their association was impaired 
in presence of the drug. This inhibitory effect of TCP is 
specific to LSD1-MYCN complex since it did not interfere 
with the interaction of MYCN with its endogenous partner 
MAX (Figure 3B). In contrast, SP2509 did not inhibit 
the interaction between LSD1 and MYCN. Also LSD1/
CoREST association was inhibited by SP2509, not by 
TCP (Figure 3C). Collectively these results demonstrate 
that LSD1 activity is necessary for the interaction with 
MYCN, not with CoREST. Thus, inhibition by TCP or 
SP2509, de-represses NDRG1 expression, albeit the two 
drugs have a marked different mode of action. 
Since SP2509 is a reversible inhibitor of LSD1, 
we tested whether re-activation of NDRG1 by SP2509 
treatment was reversible. Tet-21/N cells were treated 
with SP2509 for 48 hrs and then cells were washed, fed 
with normal medium and collected at 12, 24 and 48 hrs 
thereafter SP2509 wash out. Results in Figure 3D shows 
that NDRG1 expression decreases in a time dependent 
manner following removal of the SP2509, demonstrating 
that NDRG1 activation is directly dependent upon LSD1 
inhibition. 
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Figure 2: A. Schematic representation of the NDRG1 promoter. B. and C. MYCN and LSD1 binding to NDRG1 chromatin. Cell 
treatments are indicated at the bottom of the figure. qPCR was performed with primers for NDRG1 TSS, and -10kb. D. and E. Histone 
modifications at NDRG1 chromatin; ChIPs were carried out using the indicated antibodies and analyzed with primers encompassing the 
TSS region and -10kb from TSS. Values from three independent ChIP assays are presented along with standard deviations, n = 3. Changes 
in % input are shown normalized over IgG controls and are all statistically significant (P < 0,05; Student t test). 
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Figure 3: A. NDRG1 gene expression was determined by qRT-PCR or by western blot in Tet-21/N cells treated with SP2509 at 
different concentrations, as indicated. *, statistical significance (P < 0.01; Student t test). B. Co-Immunoprecipitation with MYCN 
antibody was performed in 293T cells co-transfected with LSD1 and MYCN expression vectors and treated with TCP, SP2509 or vehicle. 
Extract were analyzed by western blotting with MYCN, LSD1 and MAX antibodies as indicated. C. Interaction between endogenous 
LSD1 and MYCN in Tet-21/N cells, treated with TCP, SP2509 or vehicle, was assessed by co-Immunoprecipitation. Cell lysates were 
immune-precipitated with a LSD1 antibody Western blot analysis was performed on immuno-precipitated extracts with LSD1 and RCOR1 
antibodies. IgG-sample was used as negative control. D. Tet-21/N cells were treated for 48 h with SP2509 or vehicle and then released into 
fresh medium for the indicated times. Cellular extracts were prepared and stained with anti-NDRG1 and phospho-NDRG1 (Thr 346). E. 
and F. Cell extracts from SK-N-BE (2) and SH-SY5Y cells treated with SP2509 at the indicated concentrations were prepared and probed 
with NDRG1 antibody. Actinin was probed as loading control. 
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To address if LSD1 inhibition affects NDRG1 
expression in the context of MYCN amplification, 
we analyzed the effect of SP2509 in a non-amplified 
MYCN SH-SY5Y cell line. Moreover, since activation 
of NDRG1 may also occurs as result of p53 binding in 
colon cancer cell lines [35] we also used the p53 mutated, 
MYCN-amplified NB cell line SK-N-BE (2) to address 
the relative contribution of p53 in NDRG1 activation. The 
SH-SY5Y (MYCN non-amplified) and MYCN-amplified 
p53 mutated SK-N-BE (2) cells were treated with SP2509 
at different concentration for 48 hrs and western blot was 
performed using the NDRG1 antibody. Results reported 
in Figure 3E, 3F show that up regulation of the 48 kDa 
NDRG1 band is observed in both cell lines demonstrating 
that NDRG1 activation by LSD1 inhibition is not due to 
p53 activity and is not cell specific. 
Collectively our results demonstrate that 
NDRG1 expression is modulated by LSD1 and that 
pharmacological LSD1 inhibition in NB cells up-regulates 
NDRG1 expression. 
Effect of LSD1 inhibition on migration and 
invasion of NB cells
NDRG1 over-expression promotes formation of 
adherent junctions and inhibits cell migration and invasion 
in several types of tumors cells indicating that NDRG1 
inhibits the establishment of the epithelial-mesenchymal 
transition (EMT) program [18, 36]. Our findings suggest 
that LSD1 pharmacological silencing might control 
EMT in NB tumor cell lines by upregulating NDRG1 
expression. 
LSD1 was demonstrated to activate the Wnt/β-
catenin signaling pathway by down-regulating the 
pathway antagonist DKK1 in colorectal cancer cells [37]. 
In different studies NDRG1 overexpression has been 
shown to inhibit β-catenin phosphorylation inducing its 
accumulation at cell membranes [21]. We examined if 
NDRG1 activation mediated by pharmacological inhibition 
of LSD1 affected β-catenin subcellular localization. To 
this end we performed immunofluorescence to detect 
β-catenin in Tet-21/N cells untreated (Ctrl) or treated 
with SP2509. As shown in Figure 4A, SP2509 enhanced 
β-catenin accumulation on cellular membrane. A modest 
increase of β-catenin protein levels was detected in Tet-
21N and SH-SY5Y cells by immuno-blotting, Figure 4B, 
suggesting that SP2509 treatment enhanced β-catenin 
accumulation on cellular membrane. Consistent with such 
effect, expression of the β-catenin downstream target, 
Cyclin D1 was down-regulated in LSD1 inhibited cells. 
These results indicate that pharmacological treatment of 
NB cells with LSD1 inhibitor results in NDRG1 activation 
and suggest that the anti-metastatic activity of NDRG1 
in NB occurs at least in part through accumulation of 
β-catenin at cell membrane.
We then asked whether treatment with LSD1 
inhibitors and over-expression of NDRG1 might impair 
the migration and invasion of tumor NB cell lines. 
Untreated Tet-21/N (High MYCN), tetracycline-treated 
(Low MYCN) and the SH-SY5Y cells were used in 
wound-healing assays in presence or absence of TCP or 
SP2509. Both Tet-21/N (High MYCN) and SH-SY5Y 
cells filled almost completely the wounded area 24hrs 
after scratching the cell monolayer, while Tet-21/N (Low 
MYCN) showed impaired migration efficiency (Figure 5A 
and 5B). TCP or SP2509 treatment markedly suppressed 
repair of the wound area. Such inhibitory effect was 
enhanced in Low-MYCN cells suggesting that reduction 
of MYCN levels cooperates with LSD1 in blocking the 
migration of LSD1-KD cells. Next, we tested the effect of 
NDRG1 over-expression on cell invasiveness of Tet-21/N 
and SH-SY5Y cells. Both cell lines were transfected with 
a human expression vector for NDRG1, whose expression 
Figure 4: A. Tet-21/N cells were treated with SP2509 or vehicle, fixed and processed for anti-β-catenin immunofluorescence and 
DAPI staining. B. Western blot assay of protein extracts of Tet-21/N and SH-SY5Y cells treated as indicated using β-catenin and Cyclin 
D1 antibodies. α-tubulin has been probed as loading control. *, P < 0,01.
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was assayed by Western blots, Figure 5C. We determined 
that overexpression of NDRG1 recapitulates the inhibitory 
effects exerted by LSD1 inhibitors. Next, we determined 
the effect of LSD1 inhibition and NDRG1 over-expression 
on cell invasion (Figure 6). Using the trans-well migration 
assay, we showed that NDRG1 overexpression as well as 
LSD1 pharmacological inhibition in both Tet-21/N and 
SH-SY5Y cells resulted in a significant reduction ( ≥ 25%) 
of migratory capacity compared with control cells.
These findings demonstrated that pharmacological 
inhibition of LSD1 blocks migration and invasion of 
neuroblastoma cells and most importantly overexpression 
Figure 5: LSD1 inhibition reduces migration of Neurobastoma cells. A. Wound healing of Tet-21/N (High MYCN), Tetracycline-
treated Tet-21/N (Low MYCN) and B. SH-SY5Y cells treated with vehicle, TCP or SP2509. C. Wound healing was performed in Tet-21/N 
and SH-SY5Y cells 3XFlag-NDRG1 or mock transfected. Migration was assessed under treatment conditions at several time points using 
a scratch wound assay. Representative phase contrast images were shown acquired at 24hrs after scratch. Western blot shows NDRG1 
protein levels in 3xFlag-NDRG1 or mock transfected Tet-21/N and SH-SY5Y cells. Actinin was used as loading control. Graphs showing 
the results represent the mean ± SD of three independent experiments carried out in duplicate. Statistical significance P < 0,01.
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of NDRG1 recapitulate these effects. Collectively, these 
findings demonstrated that pharmacological inhibition of 
LSD1 suppresses the mobility and invasiveness of cancer 
cells through up-regulation of NDRG1.
NDRG1 expression during differentiation and in 
NB tumors
It had been shown that LSD1 expression is reduced 
following in vitro induced differentiation of neuroblastoma 
cells [14, 38]. The findings reported above indicated 
that high levels of LSD1 inversely correlate to NDRG1 
expression. To address the relative expression levels of 
MYCN, LSD1 and NDRG1 during differentiation, SK-N-
BE(2) cells were induced to differentiate by treatment with 
RA. Cell samples were collected at different time points 
after treatment and analyzed for LSD1 and NDRG1 and 
MYCN expression levels. As shown in Figure 7A, in vitro 
induced differentiation results in reduction of LSD1 and 
MYCN expression along to a concomitant up-regulation 
of NDRG1 levels. These results further confirm the 
role of LSD1 on NDRG1 expression and highlight their 
antagonism during differentiation of NB cells. Moreover 
these data strongly suggest that NDRG1 can be used as 
marker of neuroblastoma differentiation in vivo.
To further corroborate the mutually exclusive 
expression of NDRG1 and LSD1 we examined the 
relevance of NDRG1 in neuroblastoma patients. 
Independent studies have shown that low NDRG1 levels 
Figure 6: Trans-membrane migration assay of Tet-21/N and SH-SY5Y cells treated with vehicle, TCP or SP2509, or 
NDRG1-transfected. Graphs showing the results represent the mean ± SD of three independent experiments carried out in duplicate. 
*, P < 0,05.
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Figure 7: A. SK-N-BE (2) cells were treated with RA up to 9 days. LSD1, NDRG1 and MYCN protein levels were detected in 
differentiated SK-N-BE (2) cells at the indicated days by western blotting. NDRG1 expression is associated with good outcome and 
differentiated tumors. B. and C. Low NDRG1 expression is associated with negative prognosis. The number of tumors is indicated in 
parentheses. Kaplan-Meier analysis is shown, with individuals grouped by median of expression of NDRG1. Log-rank P values are shown. 
Changes in expression for LSD1 D. and NDRG1 E. in ganglioneuroblastoma (GNB), ganglioneuroma (GN) and neuroblastoma (NB). F. 
Inverse correlation between the expression values of NDRG1 and LSD1 in NB tumors (Pearson’s correlation coefficient is shown). G. Box 
plot showing differential NDRG1 expression in NB tumors without (Low) or with (High) MYCN amplification.
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are associated with worse prognosis for patients with 
breast, glioma, colorectal, esophageal squamous cell 
carcinoma, and prostate cancer [19]. More recently, it 
has been reported that low levels of NDRG1 is associated 
with poor prognosis in neuroblastoma patients [39]. In 
sharp contrast, LSD1 expression inversely correlates 
with differentiation and adverse outcome [14, 38] of 
neuroblastoma. Our in vitro findings imply that also in 
patients high LSD1 and low NDRG1 levels should be 
inversely correlated in metastatic Neuroblastomas. To 
this end we analyzed available RNAseq data of 498 NBs 
and we found that high NDRG1 expression correlates 
with better overall and event-free survival (Figure 7B 
and 7C, Mann-Whitney test, P = 3.7x10-7 and P = 8.8x10-
10). Next, we analyzed LSD1 and NDRG1 expression in 
a microarray gene expression data of 59 NBs, of which 
50 were neuroblastoma and 9 were ganglioblastoma and 
ganglioneuromas. LSD1 expression was considerably 
higher in neuroblastoma than in ganglioblastomas and 
ganglioneuromas (Figure 7D). In contrast, NDRG1 
expression was higher in well-differentiated tumors 
(Figure 7E). Thus, LSD1 and NDRG1 appear to be 
expressed in opposite fashion in NB. Accordingly, 
we found that the expression of NDRG1 is inversely 
correlated with the expression of LSD1 (Figure 7F, P = 
6.5x10-5). Finally, we determined that NDRG1 expression 
levels were appreciably lower in MYCN-amplified 
NB samples (Figure 7G). Collectively, these findings 
demonstrated that high levels of LSD1 and NDRG1 
expression are mutually exclusive in neuroblastoma, and 
the expression levels of NDRG1 are significantly lower in 
MYCN-amplified tumors.
DISCUSSION
In the current study, we demonstrated that LSD1 
in cooperation with MYCN controls cell migration and 
invasiveness of neuroblastoma cells through transcription 
regulation of the metastatic suppressor NDRG1. Our 
findings support a previously unidentified model to 
control EMT in neuroblastoma, proposing that epigenetics 
changes caused by LSD1 inhibition lead to up-regulation 
of NDRG1 thereby inducing an NDRG1-dependent 
inhibitory effect on cell migration and invasiveness of 
neuroblastoma cells
We found that in neuroblastoma cells the MYCN/
LSD1 complex binds and represses NDRG1 expression. 
Following LSD1 inhibition epigenetics changes occur 
on the chromatin region surrounding the transcriptional 
start site of NDRG1 leading to transcription activation 
of NDRG1 gene expression. In a recent study it has 
been shown that the signal cascade mTORC2/serum 
glucocorticoid induced protein kinase1 (SGK1) 
phosphorylates NDRG1 [20]. It is likely that LSD1-KD 
may also affect mTORC2/GSK1 pathway, clearly further 
investigations are required to clarify the role of LSD1 in 
the phosphorylation of NDRG1.
LSD1 inhibition suppresses motility and 
invasiveness of NB cells and ectopic over expression 
of NDRG1 phenocopy the pharmacological treatments 
with LSD1 inhibitors, suggesting that de-repression of 
NDRG1 expression plays a causative role in blocking cell 
migration and invasiveness. Moreover, lowering MYCN 
expression we observed a cooperative inhibition with TCP 
to restrain cell mobility, suggesting that MYCN and LSD1 
cooperatively control EMT.
High-risk neuroblastoma (NB) with MYCN 
amplification is a highly metastatic tumor in children. 
NB presenting with hematogenesis metastasis is one 
of the most difficult cancers to cure [1, 40]. EMT is an 
important process that contributes to tumor invasion 
and dissemination [41]. How MYC control EMT is 
largely unknown [42]. EMT process requires extensive 
reorganization of the epigenetic information of the 
cells. Previous works showed that SNAIL represses 
transcription of epithelial genes such as E-cadherin, 
by recruiting repressive chromatin-modifying factors 
including Polycomb repressive complex 2 and LSD1-
CoREST complex [41]. Our findings of targeting NDRG1 
expression through LSD1 inhibitors add new insight on 
how MYCN may control EMT. Thus, LSD1 controls EMT 
through at least two different mechanisms, as co-factors of 
SNAI1 function and in association with MYCN as a direct 
epigenetic regulator of NDRG1 expression. Previous work 
showed that blocking interactions of LSD1 with SNAI1 
blocks NB cell invasion [43]. The findings reported here 
add further support to the critical role of LSD1 in EMT 
and most importantly highlight an additional mechanism 
through which LSD1 inhibition affects cell migration and 
invasiveness of NB cancer cells. Clearly multiple signaling 
pathways cooperate in the initiation and progression of 
EMT and cooperation between different pathways likely 
occurs in a synergistic manner and in a cell-type specific 
fashion. 
Therapy for high-risk patients includes 
differentiating agents. Previous studies showed that 
NDRG1 expression is regulated by differentiation-related 
environments [19]. We determined that during RA-
mediated in vitro differentiation of NB cells the NDRG1 
protein increases during time and inversely correlates with 
LSD1 and MYCN protein expression. Thus, these data 
address that NDRG1 is a biologically important MYCN/
LSD1 target, and it is inversely expressed in relation to 
MYCN and LSD1 during NB differentiation. 
The relative expression levels of NDRG1, LSD1 
and MYCN were further analyzed in neuroblastoma 
patients. Analysis of publicly available expression data 
of large number of NBs highlighted that high NDRG1 
expression correlates with better overall and event-free 
survival. Interestingly, high levels of LSD1 and NDRG1 
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expression are mutually exclusive in neuroblastoma 
tumors and NDRG1 expression levels are significantly 
lower in MYCN-amplified NB samples. Collectively, these 
findings support and corroborate the broad significance of 
our in vitro results, and suggest that NDRG1 and LSD1 
expressions can be considered as valuable biomarkers to 
monitor NB development in humans.
In summary, our findings uncover a previously 
unidentified model in the control of EMT, suggesting 
that MYCN/LSD1 inhibition de-represses NDRG1 
expression, thereby inducing an NDRG1-dependent 
inhibitory effect on cell migration and invasiveness of 
neuroblastoma cells. These findings raise the possibility 
that improved approaches aimed to target the epigenetic 
control of NDRG1 expression may lead to development 
of novel strategies to inhibit the invasive potential of 
neuroblastoma cells.
MATERIALS AND METHODS
Cell culture and treatments
Human HEK 293T, SH-SY5Y and SHEP Tet-
21/N cells were cultured in Dulbecco’s modified Eagle’s 
Medium (DMEM) supplemented with antibiotics, 10% 
fetal calf serum. SK-N-BE (2) was cultured in 1:1 mixture 
DMEM/F-12 containing 10% FBS. All cell lines were 
incubated at 37°C in humidified atmosphere with 5% 
CO2. Tet-21/N cells are cultivated with (Low MYCN) 
or without (High MYCN) tetracycline (6 days). When 
indicated, cells were treated with TCP (1mM, Enzo Life 
Sciences), SP2509 (0,3/0,5/1 µM, Cayman Chemical 
Company) or 10054-F4 (75 µM, Sigma) for 24 or 48 
hrs. To induce differentiation in SK-N-BE (2) cells were 
exposed to 10 µM all-trans Retinoic Acid for 9 days. 
LSD1 Knock-Down
100 nM siRNA targeting LSD1 (GE Dharmacon) 
or scramble were transfected in Tet-21/N cells using 
a MicroPorator Digital Bio Technology, according to 
the recently described protocol [6]. Briefly, 2x106 cells 
were collected by trypsin/EDTA digestion, washed once 
with calcium and magnesium-free PBS and resuspended 
in 100 μl of resuspension buffer, mixed with siRNA 
or scramble and electroporatated according to the 
manufacturer’s protocol. Transfected cells were seeded in 
a 100 mm dish in antibiotic-free DMEM supplemented 
with 10% FBS. The efficiency of siRNA to knockdown 
LSD1 protein expression was assayed 48h after 
transfection by western blot.
RNA sequencing
RNA was prepared from Tet-21N cells treated 
with TCP or with siLSD1 and control untreated cells. 
RNA-seq libraries (two biological replicas for each 
sample) were generated using TruSeq RNA Sample 
Prep Kit v2 (Illumina) according to the manufacturer’s 
recommendation. All the high-throughput sequencing 
experiments were run on a NexSeq 500 (Illumina) 
sequencer at the Genomix4life S.R.L., Baronissi, Salerno, 
Italy, according to standard operating procedures. Raw 
sequences files (-fastaq files) were aligned to the human 
genome (h19 version), gene-level quantification was 
performed using R-SEM and UCSC annotation [44]. 
Subsequently, data were normalized with VOOM method 
[45] and differential expression evaluated with limma 
Bioconductor packages. Differential expressed genes 
were detected applying the following cutoff: log2 Fold 
Change ≥ 1 and FDR ≤ 0.1. RNA-seq data were deposited 
to NCBI GEO and are available under accession number 
GSE80753.
RNA extraction and qRT-PCR
RNA was extracted from NB cells using EuroGold 
Trifast (EuroClone). cDNA was generated using 
Quantitec Reverse Transcription Kit (Qiagen), according 
to manufacturer’s protocol. Quantitative analysis was 
performed using SYBR Green 2X PCR Master Mix 
(Applied Biosystem). Each sample was run in triplicate 
and normalized to the expression of housekeeping beta-
glucoronidase (GUSb) gene as previously described [6]. 
Primers are presented in Supplementary Table S1.
Protein extraction and western blot
Whole-cell extracts were obtained using buffer F (10 
mM TrisHCl pH 7.5, 150 mM NaCl, 30 mM Na4O7P2, 
50 mM NaF, 5 mM ZnCl2, 0.1 mM Na3VO4, 1% Triton, 
0.1mM PMSF). 50 μg of protein extracts were loaded 
and separated by SDS-PAGE and WB was performed 
with indicated antibodies. For NDRG1 silencing in Tet-
21/N cells, 3 µg/106 cells of shRNA plasmid (Santa Cruz) 
targeting NDRG1 was used with the protocol described 
above.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were 
performed as recently described [6]. Briefly 1x107 
cells were cross-linked using formaldehyde to a final 
concentration of 1% and reaction was stopped using 
0.125M Glycine. Cell pellet was resuspended in Cell Lysis 
Buffer and after 6000 rpm centrifugation RIPA buffer 
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were added to perform nuclei lysis. DNA shearing was 
conducted by sonication using Bioruptor (Diagenode). 
A small aliquot of sonicated material was put aside and 
remaining sample immunoprecipitated using 5 micrograms 
of ChIP-grade antibodies. Rec-sepharose Protein A or 
G beads (Invitrogen) were used to immobilize immuno-
complexes and after RNAse-A treatment (37°C 1 hour) 
reverse cross-linking were performed using Proteinase 
K (Roche) for 6 hours at 65°C. Immunoprecipitated 
DNA was purified using Phenol/Chloroform and Ethanol 
precipitation techniques. The antibodies used are listed in 
Table S2. The immunoprecipitated DNA was quantified by 
qPCR with the primer sets described in Table S1. 
Migration assays
In migration experiments, 2,5 µg/106 cells of 
3xFLAG-NDRG1 or empty vector were transiently 
transfected into Tet-21/N by electroporation, by protocol 
as described previously. For transient transfections of SH-
SY5Y, cells cultured on 100 mm dishes were transfected 
with 3xFLAG-NDRG1 plasmid or empty vector using 
Lipofectamine 2000 according to manufacturer’s protocol. 
The expression of protein was determined by western 
blot. For the wound-healing assay, NDRG1-trasfected or 
control cells were plated to confluence in a 12-well plate 
and scraped with a p200 pipet tip to create a scratch of 
the cell monolayer; when indicated cells were treated 
with TCP or SP2509 for an overnight before scratch and 
during the whole experiment. Cells were then allowed 
to fill the wounded area for 2 days and images were 
acquired using a Nikon Eclipse TE 2000-U microscope. 
Percentage of wound healing was measured as following: 
[(empty area at T0)-(empty area at 24hrs)]/(empty area at 
T0) x 100. For trans-membrane migration assay, cells were 
NDRG1-transfected or pre-treated with TCP or SP2509 
for an overnight, before plating (150000 cells/chamber) 
in free serum medium in the upper side of chambers (BD 
Falcon Cell Culture Inserts). In the wells 20% of FBS was 
used as chemo-attractant. After 24 h, non-migrating cells 
were scraped-off, whereas migrating cells were stained 
with a 20% ethanol-1% crystal violet solution for 10’, 
washed thrice with water and counted at least in ten fields 
with a 10x objective. For each assay three independent 
experiments were carried out in duplicate. 
Co-immunoprecipitation
Co-immunoprecipitation assays were performed 
using Tet-21/N and HEK 293T cells. 293T cells were 
transiently co-transfected with 3xFLAG-LSD1, 3xFLAG-
MYCN or scramble by the polyethylenimine (PEI 25 K) 
method. 1 mg of protein extract from Tet-21/N cells or 0,3 
mg from HEK 293T cells, treated with TCP, SP2509 or 
vehicle, were incubated respectively with LSD1 or MYCN 
antibody and processed as previously described [6, 46]. 
Protein interactions were assessed by immunoblotting 
using the indicated antibodies. 
Immunofluorence
For immunofluorescences assay Tet-21/N were 
seeded on coverslips and treated as indicated. Cells were 
than fixed in 4% paraformaldehyde in PBS, permeabilized 
in 0.1% Triton X-100 in PBS, pre-blocked in 2% BSA- 
3%NS-PBS for 30 min at room temperature, and then 
incubated for 1 h at 37° C with mouse anti-β-catenin. 
Primary antibodies were detected by incubation with 
Cy3-coniugated anti-mouse. Images were acquired using 
a Nikon Eclipse TE 2000-U microscope.
Gene expression data for survival analysis and 
association with neuroblastoma stages
Normalized gene expression data from RNA 
sequencing of 498 tumors were downloaded from “R2: 
Genomics Analysis and Visualization Platform” (GEO ID: 
GSE62564). To test association of gene expression levels 
with overall survival and event free survival, individual 
gene expression profiles were dichotomized by median 
split into ‘high’ or ‘low’ expression groups, and Kaplan-
Meier survival curves were plotted for each group. Long 
rank test was used to evaluate the significant difference 
between the two groups. Another set of gene expression 
data of 64 tumors (GEO ID: GSE12460) including 50 
NB, 6 ganglioneuroblastoma and 3 ganglioneuroma was 
downloaded. Mann-Whitney test was used to test the 
significant different gene expression among groups. The 
correlation between the gene expression between NDRG1 
and KDM1A was evaluated by Pearson correlation in 64 
NBs. The gene expression data for Low and High MYCN 
expression (493 samples) were generate by customized 
4x44K oligonucleotide microarrays produced by Agilent 
Technologies and analyzed as previously reported [47].
Statistical analysis
All experiments were repeated two or three times. 
Graphs representing data express mean ± SD. Statistical 
significance was obtained by unpaired, two-tailed Student 
t test. P < 0,05 was considered statistically significant.
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ABSTRACT 
Autophagy is a physiological process, important for recycling of macromolecules and maintenance 
of cellular homeostasis. Defective autophagy is associated with tumorigenesis and plays a 
causative role in chemotherapy resistance in leukemia and in solid cancers. Here, we report that 
autophagy is regulated by the Lysine-specific demethylase LSD1/KDM1A, an epigenetic marker 
whose overexpression is a feature of malignant neoplasia with an instrumental role in cancer 
development. In the present study we determine that two different LSD1 inhibitors (TCP and 
SP2509) as well as selective ablation of LSD1 expression, promote autophagy in Neuroblastoma 
cells. At mechanistic level we show that LSD1 binds to the promoter region of Sestrin2 (SESN2), a 
critical regulator of mTORC1 activity. Pharmacological inhibition of LSD1 triggers SESN2 
expression that hampers mTORC1 activity leading to enhanced autophagy. SESN2 
overexpression suffices to promote autophagy in Neuroblastoma cells while loss of SESN2 
expression reduces autophagy induced by LSD1-inhibition. Our findings elucidate a mechanism 
whereby LSD1 control autophagy in Neuroblastoma cells through transcription regulation of 
SESN2 expression and we suggest that pharmacological targeting of LSD1 may have effective 
therapeutic relevance in the control of autophagy in Neuroblastoma. 
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INTRODUCTION 
Cancerous cells must deal with effective mechanisms of cell death, thereby reducing activation of 
defense pathways in response to oncogenic insults.1, 2 The induction of apoptosis is the major 
route of cell death yet multiple cellular processes, including autophagy, antagonize it.  
Autophagy is a conserved intracellular process in which cytoplasmic components are degraded 
within lysosomes playing a central role in cell metabolism and homeostasis. There are different 
types of autophagy: micro-autophagy, selective autophagy, macro-autophagy and chaperone-
mediated autophagy.3 Macro-autophagy is the main autophagic pathway and consists in the 
formation of double-membrane autophagosomes that sequester cellular components and then fuse 
with lysosomes for degradation and recycling of macromolecules and organelles. Autophagy 
normally operates at low, basal levels in cells but can be strongly induced by cellular stress. 
Defective autophagy is associated with human pathologies such as bacteria and virus infections, 
neurodegenerative diseases and cancer.4-6 
Autophagy plays dual roles in cancer; it can function as either a tumor suppressor, by preventing 
the accumulation of damaged proteins and organelles, or a survival pathway, by suppressing 
apoptosis and promoting the growth of tumors.7-9 Recent studies showed that autophagy plays a 
causative role in chemotherapy resistance in leukemia10 and in solid cancers.7, 10 Nonetheless the 
molecular mechanisms underlying the effects of autophagy on tumorigenesis must be further 
elucidated.  
 Mammalian Target of Rapamycin Complex 1 (mTORC1) is the major regulator of 
autophagy. In the presence of nutrients, mTORC1 is activated, resulting in inhibition of the Ulk1 
complex and repression of autophagy.11 Following nutrient deprivation, mTORC1 is inhibited, and 
Ulk1 complexes can lead autophagosome formation. Given its pivotal role in autophagy regulation, 
mTORC1 is the main target for drugs development to modulate the autophagic pathway.12, 13  
Recently, several studies have demonstrated that autophagy is regulated by epigenetic alterations, 
including histone methylation and acetylation.14-16 The precise mechanisms through which cancer-
associated epigenetic alterations modulate autophagy have not yet been elucidated. An epigenetic 
enzyme that has been target of drug discovery is the lysine-specific demethylase 1, LSD1. LSD1 
(also known as KDM1A and AOF2) is an amine oxidase that catalyzes lysine demethylation in a 
flavin adenine dinucleotide (FAD)-dependent oxidative reaction17 and removes mono- and dimethyl 
groups from lysine K4 and, in specific circumstances, K9 on histone H3.17-19 More recently, it has 
been shown that the neuron–specific isoform LSD1n has a new substrate specificity, targeting 
histone H4 Lys 20.20 Finally, LSD1 can also targets non-histone proteins such as p53, E2F1, and 
DNMT.21-23 LSD1 has been demonstrated to play important roles in many important aspects of cell 
biology, such as cell proliferation, cell mobility and differentiation.24-26 Most importantly, LSD1 is 
overexpressed in a variety of cancers and tends to correlate with more aggressive cancers with 
poor prognosis. There is a large body of evidence that LSD1 is involved in maintaining the 
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undifferentiated, malignant phenotype of Neuroblastoma cells and that its overexpression 
correlates with aggressive disease, poor differentiation and infaust outcome.24, 27 
 In the present study, we define a novel role of the epigenetic regulator LSD1 in the 
modulation of autophagy. We found that selective ablation of LSD1, or pharmacological 
inactivation of its catalytic function, inhibits mTORC1 activity enabling enhanced autophagy. 
Mechanistically, we found that LSD1 binds to the promoter region of Sestrin2 (SESN2) and 
represses its expression. LSD1 inhibition triggers SESN2 expression that hampers mTORC1 
activity leading to Transcription Factor EB (TFEB) nuclear translocation driving the expression of 
the Coordinated Lysosomal Expression and Regulation (CLEAR) regulatory network. Taken 
together, our findings indicate that LSD1 regulates autophagy in Neuroblastoma cells via 
transcriptional regulation of SESN2 that serves as key positive regulator of mTORC1–dependent 
autophagy pathway. 
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RESULTS 
LSD1 inhibition represses mTORC1 pathway 
LSD1 is highly expressed in undifferentiated Neuroblastomas and its expression correlates 
with adverse outcome, however, the molecular mechanism underlying LSD1 effects is largely 
unknown. We initially undertook an unbiased approach to uncover how cells respond to the loss of 
LSD1 function looking at signaling alterations caused by treatment with tranylcypromine (TCP), a 
potent inhibitor of LSD1 in Tet-21/N Neuroblastoma cells. PathScan array was used to determine 
pathways involved in TCP response. In this assay mTORC1 pathway was the most responsive, 
evidenced by ribosomal protein S6 (Ser235/236), p70S6 Kinase (Thr389) and PRAS40 (Thr246) 
phosphorylation reduction (Fig. 1a). To verify PathScan array results, we performed Western blot 
analysis of mTORC1 downstream substrates, p70S6K and rpS6. Tet-21/N cells were also treated 
with SP2509, a reversible inhibitor of LSD1 that, differently from TCP does not target the catalytic 
activity of the enzyme, but attenuates the binding of LSD1 to CoREST.28, 25 In addition, to address 
the specific role of LSD1 in mTORC1 activity, we inhibited LSD1 by siRNA-targeted knockdown 
and measured expression of mTORC1 downstream targets. Protein extracts were prepared at the 
indicated times and probed with antibodies recognizing phosphorylated and total protein forms of 
mTORC1 substrates. In agreement with the array data, phosphorylation levels of p70S6K, and 
consequently of its target rpS6, were down regulated by either TCP or SP2509 treatment as well 
as in LSD1 KD cells (Fig. 1b, c). In addition, similar results were observed in SH-SY5Y 
Neuroblastoma cells (Fig. 1d). Collectively these findings demonstrated that LSD1 inhibition 
downregulates mTORC1 signaling. 
 mTORC1 is known as a critical regulator of autophagy. In response to nutrient deprivation, 
mTORC1 is inactivated and dissociates from the ULK complex, inducing autophagy activation. In 
addition mTORC1 has been shown to control autophagy through the functional regulation of the 
Transcription Factor EB (TFEB), a master regulator of lysosomal and autophagic functions. Active 
mTORC1 phosphorylates and sequestrates TFEB to the cytoplasm; on the contrary, mTORC1 
inactivation leads to de-phosphorylation of TFEB, witch translocates into the nucleus and drives 
the expression of lysosomal and autophagy genes that are part of the Coordinated Lysosomal 
Expression and Regulation (CLEAR) regulatory network.12, 29  
We sought to investigate the impact of LSD1 inhibition on TFEB subcellular localization. Tet-21/N 
and SH-SY5Y cells were treated with TCP for the indicated times and analyzed by 
immunofluorescence using a TFEB antibody. In untreated cells TFEB is localized mainly in the 
cytoplasm. Consistently with mTORC1 repression, pharmacological inhibition of LSD1 leads to a 
significant increase of TFEB nuclear levels along with a decreased cytosolic localization (Fig. 2a 
and b). This finding was further confirmed using specific siRNA against LSD1 (Fig. 2c).  
Because SP2509 is a reversible inhibitor of LSD1, we used this drug to test whether TFEB nuclear 
shuttling was directly dependent upon LSD1 inhibition. We monitored whether nuclear shuttling of 
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TFEB was reversed in time after SP2509 wash out. Tet-21/N cells were treated with SP2509 for 48 
hrs and then cells were washed and cultivated in fresh medium for additional 24 and 48 hrs after 
drug removal. The immunofluorescence results in Figure 2d show that TFEB nuclear localization 
decreases in a time dependent manner following SP2509 wash out, demonstrating that TFEB 
nuclear localization is directly dependent upon LSD1 inhibition. 
 
LSD1 depletion induces autophagy  
 Autophagy begins with the sequestration of cytosolic proteins in a double membrane 
structure called autophagosome. Following fusion with a lysosome it becomes an 
autophagolysosomes, then lysosomal hydrolases degrade the content of the phagosome that is 
released in the cytosol for the recycling of macromolecules. During autophagosome formation, the 
cytosolic form of the microtubule-associated protein 1A/1B-light chain 3 (LC3-I) is conjugated to 
phosphatidylethanolamine to form lipidated-LC3 (LC3-II), which becomes associated with 
autophagosomal membranes. Tet-21/N cells were treated with TCP (Fig. 3a) or siLSD1 transfected 
(Fig. 3b) and then processed for Western blot analysis to monitor the conversion from LC3-I to 
lower-migrating form LC3-II, as well-established marker of autophagosomes formation.30 TCP 
treatment induced LC3-II form accumulation over time compared with control cells (Fig. 3a). 
Moreover, LSD1-KD also increases LC3-II form level in a dose dependent manner (Fig. 3b). 
Similar findings were observed in SH-SY5Y cells (Supplementary Figure 1). Because LC3-II 
increment might also be interpreted as autophagosome accumulation due to the block of 
autophagosome-lysosome fusion, we evaluated the autophagic flux following LSD1 inhibition using 
a GFP-mRFP-tandem tagged LC3. Indeed, by taking advantage of the properties of these two 
fluorescent proteins (GFP signal is quenched inside the acidic lysosomal lumen, but not mRFP) we 
can discriminate between autophagic compartments before and after fusion with lysosomes.30, 31  
Tet-21N cells were transiently transfected with the GFP-mRFP-LC3 tandem construct and treated 
with TCP alone or in combination with NH4Cl to block autophagolysosomal degradation by 
preventing its acidification. In untreated cells GFP and mRFP signals appear mainly diffused in the 
cytosol and with few puncta (Fig. 3c). Conversely, the number of green and red puncta was higher 
following TCP treatment, indicating that LSD1 inhibition enhanced the autophagic flux (Fig. 3c, 
upper graph). Moreover, a significant increase of autolysosomes (mRFP positive, but GFP-
negative puncta) was observed upon TCP treatment (Fig. 3c, lower graph), indicating that the 
autophagosome maturation is occurring. Consistently, upon combined treatment of TCP and 
NH4Cl green dots were augmented as expected by the fact that NH4Cl, increasing the 
intralysosomal pH, prevents GFP quenching (Fig. 3c).  
Taken together, these results clearly indicate that pharmacological inhibition of LSD1 activity 
triggers a functional autophagic flux induction, as demonstrated by the nuclear localization of 
autophagy master regulator TEFB and the mature autophagolysosomes formation. 
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LSD1 inhibition promotes autophagy by increasing SESN2 expression 
 To understand the mechanisms by which LSD1 inhibition induces autophagy, we analyzed 
data from our recent published RNA-seq from Tet-21/N cells treated with TCP or siLSD1.25 Among 
the common up-regulated genes we identify Sestrin2 (SESN2) as a LSD1 repressed target gene. 
SESN2 is a member of an evolutionarily conserved stress-inducible Sestrin gene family and it has 
been shown that SESN2 directly inhibits mTORC1 activity via GATOR2 with a consequent 
inhibition of mTORC1 recruitment to the lysosomal membrane.32, 33 Through these functions, 
SESN2 serves as key positive regulator of the autophagic pathway. To validate RNA-seq data we 
inhibited LSD1 in Tet-21/N cells with TCP or siRNA against LSD1 and assayed SESN2 mRNA and 
protein expression. Accordingly, with our RNA-seq data, we found that LSD1 inhibition or silencing 
enhances SESN2 expression (Fig. 4a). 
Next, we sought to determine whether LSD1 is directly involved in control of SESN2 gene 
expression. Public available ChIP-seq LSD1 data from SH-SY5Y cells as well as from mouse ES 
cells indicate a putative LSD1 binding to the promoter region of SESN2 (Supplementary Figure 2). 
We then carried out Chromatin IP assays to determine binding of LSD1 to SESN2 chromatin. 
LSD1 binding was analyzed in Tet-21/N cells treated with TCP or silenced for LSD1 expression. 
Chromatin isolated from Tet-21/N cells was immunoprecipitated with anti-LSD1 antibody and 
analyzed by qPCR, using primers corresponding to the 5’ regulatory regions surrounding the 
transcription start site (TSS) of the SESN2 gene. As shown in Fig. 4b, LSD1 is recruited selectively 
at TSS of the SESN2 gene but not at distal sites (-10kb), indicating that LSD1 binds to the SESN2 
promoter.  
To better understand how LSD1 can affect chromatin organization at SESN2 promoter, we 
analyzed four different histone modifications, H3 pan-acetyl (H3Ac), H3K27Me3, H3K4Me2 and 
H3K9Me2 around TSS promoter region. Fig. 4c shows that both LSD1 silencing (siLSD1) and 
inhibition by TCP determine a significant increase in H3 acetylation. As a marker of transcriptional 
repression we analyzed Lysine 27 tri-methylation of Histone H3. Data presented in Fig. 4d 
demonstrate that both LSD1 silencing or its inhibition (TCP) determine an almost 2,5 fold decrease 
of the marker. Chromatin-IP assays were also performed on di-methylated Lysine 4 of histone H3 
(Fig. 4e) and we found a significant increase of H3K4me2 at SESN2 TSS following LSD1 inhibition. 
Conversely, both inhibition and repression of LSD1 do not affect H3K9Me2 signature at TSS level 
of SESN2 (Fig. 4f). These findings highlight the critical role of LSD1 in the transcriptional regulation 
of SESN2 gene through direct binding to SESN2 promoter.  
 It has been recently shown that LSD1-depletion, synergistically with UBE4B inhibition, 
increases proteasomal and autophagy clearance activating the p53-mediated transcriptional 
program.34 TP53/p53 is involved in the regulation of autophagy through two distinct mechanisms, 
according to its sub-cellular localization: cytoplasmic p53 inhibits autophagy through the inhibition 
 8
of AMPK and the subsequent mTOR activation; nuclear p53 induces the transcription of pro-
autophagic genes, including SESN2.35-37 To verify that SESN2 up-regulation mediated by LSD1 
inhibition occurs in a p53-independent manner, we employed SK-N-BE (2) neuroblastoma cell line, 
which expresses a non-functional p53.38 Cell extracts from SK-N-BE (2) cells treated with TCP, 
SP2509 or vehicle were processed and assayed for SESN2 expression. As shown in Figure 5a, 
both inhibitors induce significant increase of SESN2 protein levels, together with a strong induction 
of LC3I/LC3II conversion. Furthermore, we found a SP2509 dose-dependent reduction in 
phosphorylation of mTORC1 targets, S6p70K and rpS6, confirming that LSD1-inhibition specifically 
impairs mTORC1 activity (Fig. 5b). These findings strongly suggest that p53 function was not 
essential for SESN2 transcriptional activation and mTORC1 inhibition triggered by pharmacological 
LSD1 depletion. 
 
SESN2 is required for autophagy induced by LSD1 inhibition  
 The findings reported above demonstrated that LSD1 binds and represses SESN2 gene 
expression; thus, LSD1 inhibition triggers SESN2 expression. Because SESN2 serves as 
important regulator of mTORC1 activity, we hypothesized that its up-regulation may have a 
causative role in LSD1-mediated mTORC1 activity modulation and autophagy induction. 
To substantiate the relationship between SESN2 and autophagy induction following LSD1 
inhibition, we ectopically overexpressed SESN2 in SH-SY5Y cells, and assessed the effect of 
increased expression of SESN2 on autophagy. We found that overexpression of SESN2 reduced 
rpS6 phosphorylation, along with a concomitant increase of TFEB nuclear localization. These 
findings provide functional evidences that enhanced expression of SESN2 induces autophagy 
through mTORC1 inhibition and recapitulates the effects of TCP treatment in neuroblastoma cells 
(Fig. 6a and b). To further define the role of SESN2 in autophagy induced by LSD1 inhibition, we 
performed SESN2 knockdown experiments, using a specific siRNA in SH-SY5Y cells, and 
investigated the functional consequences on LSD1 inhibition in SESN2 silenced cells. Lacks of 
appreciable changes in phosphorylation level of mTORC1 downstream targets were seen in 
siRNA-SESN2 cells (Fig. 6c). In contrast, reduction of phosphorylation levels of p70S6K and rpS6 
induced by TCP treatment is significantly weakened in SESN2 silenced cells; these data suggest 
that TCP requires SESN2 expression to decrease mTORC1 activity. Moreover, in SESN2 
knockdown cells we found a reduced nuclear translocation of TEFB following TCP treatment (Fig. 
6d), indicating that SESN2 knockdown prevents the LSD1 inhibition-mediated autophagy. Taken 
together, these results identified SESN2 as a key player in the autophagy activation mediated by 
LSD1 inhibition. 
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DISCUSSION 
LSD1 is overexpressed in several types of cancers and its enhanced expression correlates with 
more aggressive cancers and poor prognosis. LSD1 is implicated in several biologic processes, 
such as cell proliferation, epithelial-mesenchymal transition, stem cell pluripotency and 
differentiation.24-27, 39 However, its involvement in autophagy regulation is still poor characterized. 
Here we show that pharmacological and genetic inhibition of LSD1 induces autophagy via the 
mTORC1-dependent pathway. 
The present work highlights a critical role of LSD1 in promoting autophagy in neuroblastoma cells; 
we provide for the first time evidences supporting the role of LSD1 as epigenetic regulator of 
autophagic pathway through the modulation of SESN2 expression. 
We demonstrated that LSD1 binds and represses the SESN2 gene; alteration of chromatin 
structures following LSD1 inhibition leads to the de-repression of SESN2 gene, which resulted in a 
decreased mTORC1 activity. Thus, LSD1 inhibition triggers autophagy, as demonstrated by 
mTORC1 inhibition, nuclear translocation of TFEB, accumulation of LC3-II and finally the formation 
of autophagosomes, suggesting a direct link between LSD1-specific transcriptional regulation, 
mTORC1 cascade and autophagy.  
Recent works highlight the involvement of LSD1 in the autophagic machinery. Indeed, in prostate40 
and ovarian cancer cells41 LSD1 inhibition triggers LC3-II accumulation and autophagosomes 
formation, however the molecular mechanism underlying these effects was not described. 
Here, we identify SESN2 as an LSD1 repressed target gene involved in mTORC1 pathway control. 
We found that SESN2 promoter is directly bound and repressed by LSD1; pharmacological 
inhibition of LSD1 triggers a structural modeling in the chromatin surrounding the TSS of SESN2 
gene, leading transcriptional activation of SESN2 expression. Moreover, we demonstrated that 
SESN2 enhanced expression suffices to promote autophagy in Neuroblastoma cells and SESN2 
silencing attenuates mTORC1 suppression and autophagy induction by LSD1 inhibition, providing 
evidence that SESN2 has a critical role in the autophagy activation mediated by LSD1 depletion. 
SESN2 is a member of the sestrin family of PA26-related proteins, which plays an important role in 
regulating the cellular response to oxidative stress. TP53/p53 is the master transcriptional 
regulator of SESN2 under DNA damage and oxidative stress.37, 42 Interestingly, it has been 
recently shown that LSD1-depletion, synergistically with UBE4B inhibition, increases proteasomal 
and autophagic clearance activating the p53-mediated transcriptional program.34 We find that 
depletion of LSD1 induces activation of SESN2 expression in SK-N-BE (2) cell line, which express 
non-functional p53. Thus, LSD1 appears to regulate transcription of SESN2 in both p53-dependent 
and p53-independent ways. 
We recently reported that the MYCN/LSD1 complex inhibits the transcription of the molecular 
chaperone Clusterin39, which is involved in the autophagic process thought the stabilization of the 
LC3-Atg3 heterodimer, increasing the autophagosome biogenesis and autophagy progression43; 
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we suggest that LSD1 orchestrates a broad-spectrum regulation of autophagic pathway via 
transcriptional regulation of several autophagy-related genes. 
Autophagy is a catabolic process that, at basal levels, represents the major mechanism for the 
turnover of cytoplasm components and selective removal of unfolded proteins and damaged 
organelles. However, autophagy could be activated in response to several stimuli such as 
oxidative and nutrient stresses and the mTOR-pathway is the main regulator.12, 35 Recent studies 
suggest that the mTORC-pathway may be associated with cancer-related epigenetic alterations1, 44, 
45, unveiling a key role of the epigenetic network in the autophagy control. HDACI inhibitors have 
been shown to induce autophagy via FOXO1-dependent pathways46; the methyltransferase EZH2 
has been demonstrated to repress several negative regulators of the mTOR pathway and inhibits 
autophagy.47 However, epigenetic role in autophagy regulation and its association with 
tumorigenesis continues to be uncovered.  
The relationship between autophagy and cancer remains controversial. Autophagy seems to have 
a dual effect in cancer, depending on stage and cell type, and it could act as tumor suppressor or 
driver of cancer progression.7, 9 Some tumors are sensitive to hyper-activation of autophagy; in 
other circumstances, inhibition of mTORC1 increases cell survival and prevents apoptosis, 
inducing chemoresistance.48 Although relationship between autophagy and tumor progression is 
disputed, during early stages of carcinogenesis autophagy seems to suppress tumor initiation and 
cancer development is often associated with defective autophagy.7, 9 We cannot exclude that LSD1 
overexpression may contribute to tumor initiation by suppressing the expression of key regulators 
of autophagy induction, although further studies are required to clarify this issue. 
In conclusion, data reported here establish the critical role of LSD1 in autophagy and indicate that, 
in neuroblastoma cells, LSD1 knockdown induces autophagy through the SESN2-mTORC1 
pathway. Our results strongly support the concept that LSD1 dependent epigenetic alterations may 
influence the expression of autophagy-related-genes and provide a novel link among epigenetic 
regulation, mTOR pathway, and tumorigenesis.  
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MATERIALS AND METHODS 
Cell culture and treatments 
SH-SY5Y and SHEP Tet-21/N cells were cultured in Dulbecco’s modified Eagle’s Medium (DMEM) 
supplemented with antibiotics, 10% fetal calf serum. SK-N-BE (2) was cultured in 1:1 mixture 
DMEM/F-12 containing 10% FBS. All cell lines were incubated at 37°C in humidified atmosphere 
with 5% CO2. When indicated, cells were treated with TCP (1mM, Enzo Life Sciences) or SP2509 
(0,2/ 0,5 /1 µM, Cayman Chemical Company) for 6, 12, 24 or 48 hrs. 20 mM of NH4Cl was 
administrated for 24h to block autophagic flux.  
 
Transfection and silencing 
For transient transfections of Tet-21/N and SH-SY5Y, cells cultured on 100 mm dishes were 
transfected with 12 μg of SESN2 plasmid, GFP-mRFP-LC3 (kind gift of Dr. A. Fraldi, Tigem 
Institute) construct or empty vector using Lipofectamine 2000 according to manufacturer’s protocol. 
For LSD1 Knock-down 50 or 100 nM siRNA targeting LSD1 (GE Dharmacon) or scramble were 
transfected in Tet-21/N cells using a MicroPorator Digital Bio Technology, according to the recently 
described protocol.39 Briefly, 2x106 cells were collected by trypsin/EDTA digestion, washed once 
with calcium and magnesium-free PBS and resuspended in 100 μl of resuspension buffer, mixed 
with siRNA or scramble and electroporatated according to the manufacturer’s protocol. 
Transfected cells were seeded in a 100 mm dish in antibiotic-free DMEM supplemented with 10% 
FBS. The efficiency of siRNA to knockdown LSD1 protein expression was assayed 48h after 
transfection by western blot. For silencing assays 45 nM siRNA targeting SESN2 (GE Dharmacon) 
or scramble were transfected in SH-SY5Y cells using Viromer Green, according to the 
manufacturer's protocol. Cells were collected for analysis 48h after transfection. 
 
Path Scan assay 
For PathScan assay (PathScan® Intracellular Signaling Array Kit, Cell Signaling), cell lysates from 
Tet-21/N cells, treated with TCP or vehicle for 24h, were prepared according to manufacturer 
protocol; 75 μl of lysates was added to each well previously prepared with Blocking Buffer and 
slide was incubated 2h at room temperature. After incubation, slide was washed four times with 
Wash buffer and each well was incubated with 75 μl of Detection Antibody Cocktail for 1 hour at 
room temperature. Then, slide was washed three times and incubated for 30 minutes with 75 μl of 
HRP-linked Streptavidin reagent. Next, slide was washed, incubated with Lumi Glo/peroxide 
solution and displayed by biochemiluminescence acquisition. Protein expression levels were 
quantified and normalized by positive controls using ImageJ32 software. 
 
Protein extraction and Western blot 
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Whole-cell extracts were obtained using buffer F (10 mM TrisHCl pH 7.5, 150 mM NaCl, 30 mM 
Na4O7P2, 50 mM NaF, 5 mM ZnCl2, 0.1 mM Na3VO4, 1% Triton, 0.1mM PMSF). 50 μg of protein 
extracts were loaded and separated by SDS-PAGE and WB was performed with indicated 
antibodies listed in Supplementary Table S1.  
 
Immunofluorence and microscopy 
Immunofluorescences assay was carried out as previously described.25 Briefly, 2x104 cells were 
plated in a well of a 12-well plate, in which a coverslip had been placed, and treated as indicated. 
Cells were than washed, fixed in 4% paraformaldehyde in PBS, permeabilized in 0.1% Triton X-
100 in PBS for 5 min, pre-blocked in 2% BSA for 30 min at room temperature, and then incubated 
for 1 h at 37° C with rabbit anti-TFEB. Cells were then incubated for 30 min at room temperature 
with Cy3-coniugated secondary antibody and nuclei were stained with DAPI. Images were 
acquired using a Nikon Eclipse TE 2000-U microscope. 
In case of GFP-mRFP-LC3 experiments cells were just fixed in 4% paraformaldehyde and images 
were collected using a laser-scanning microscope (LSM 510 META, Carl Zeiss Microimaging, Inc.) 
equipped with a Plan Apo 63x oil-immersion (NA 1.4) objective lens. Moreover, we acquired the 
images with the same setting (laser power, detector gain) as well as we kept the same threshold of 
fluorescence intensity in all experimental conditions. Quantification analyses were carried out using 
LSM 510 software. We evaluated the autophagic flux counting the number of green and red puncta 
per cell (number of cells > 100). Student’s t-test was used to determine the significance and error 
bars represent the standard deviation (SD) of the average. 
 
RNA extraction and qRT-PCR  
Total RNA was extracted from Tet-21/N cells using EuroGold Trifast (EuroClone). The reverse 
transcription reaction was performed using Quantitec Reverse Transcription Kit (Qiagen), 
according to manufacturer’s protocol. cDNA thus obtained was analyzed by quantitative-PCR 
using SYBR Green 2X PCR Master Mix (Applied Biosystem). Each sample was run in triplicate 
and normalized to the expression of housekeeping beta-glucoronidase (GUSb) gene as previously 
described.39 Primers are presented in Supplementary Table S1. 
 
Chromatin Immunoprecipitation assay 
For ChIP assays, 1x107 cells treated as indicated were cross-linked using 1% formaldehyde. Cell 
pellet was lysed and sonicated into 200 bp fragments using Bioruptor (Diagenode). A small aliquot 
of sonicated material was put aside as input. Remaining samples were incubated an overnight with 
rotation at 4°C with 5 µg of ChIP-grade antibodies listed in Table S2; 50 µl of Rec-sepharose 
Protein A/G beads (Invitrogen) were used to immobilize immuno-complexes. After RNAse-A 
treatment (37°C for 1 hour) reverse cross-linking were performed using Proteinase K (Roche) for 6 
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hours at 65°C. Immunoprecipitated DNA was purified and quantified by qPCR with the primer sets 
described in Table S1 and normalized to input DNA.  
 
Statistical analysis 
All experiments were repeated at least two times. Graphs representing data express mean ± SD. 
Statistical significance was obtained by unpaired, two-tailed Student t test. P<0,05 was considered 
statistically significant. 
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FIGURE LEGENDS 
Figure 1. 
LSD1 inhibition represses mTORC1 activity. (a) Protein extract from Tet-21/N treated with 1 mM 
TCP or vehicle (Ctrl) for 24 h were analyzed for the signaling activation using the PathScan 
antibody arrays. Graph shows the pixel density ratio of signaling molecules dots. Values represent 
the means of two independent experiments (± s.d.). (b) Western blotting of protein extracts from 
Tet-21/N cells treated for 0, 12 or 24 h with TCP or SP2509 (1 µM) using the indicated antibodies. 
(c) Tet-21/N cells were transfected with siRNA against LSD1 at different concentration, or 
scramble (0). Cells were collected 48h after transfection and protein extracts were prepared and 
stained with the indicated antibodies. (d) Western blotting of protein extracts from SH-SY5Y cells 
treated for 24 h with TCP using the indicated antibodies. Actinin was probed as loading control. 
 
Figure 2. 
LSD1 inhibition leads to TFEB nuclear sub-localization. Tet-21/N (a) and SH-SY5Y (b) cells were 
treated with TCP or vehicle for the indicated times fixed and processed for anti-TFEB 
immunofluorescence and DAPI staining.  (c) Tet-21/N cells were transfected with scramble (Ctrl) or 
siRNA against LSD1 (100 nM), fixed and stained with anti-TEFB and DAPI (d) Tet-21/N cells were 
treated for 48 h with SP2509 or vehicle and then released into fresh medium for the indicated 
times before immuno-staining with TFEB antibody and DAPI. Histograms show the percentage of 
TFEB nuclear translocation (mean ± s.d., n=200 cells) 
 
Figure 3. 
LSD1 inhibition induces autophagy. Tet-21/N cells were treated with TCP for the indicated times 
(a), or siLSD1 at different concentrations as indicated (b), and protein extract were prepared and 
probed using anti-LC3 antibody. LSD1 protein level in cells transfected with siLSD1 or control (0) 
was shown. Actinin was probed as loading control. (c) Tet-21/N were transiently transfected with 
GFP-mRFP-LC3 tandem construct and treated with TCP alone or in combination with 20mM 
NH4CL for 24 h. After treatment, cells were fixed and analyzed by confocal microscopy. Bar, 10 . 
Histograms show the number of GFP or mCherry puncta (upper graph) or the number of only-red 
positive (GFP-negative) puncta (lower graph). The values are expressed as means ± s.d. (n>100 
cells). * p<0.00001.  
 
Figure 4. 
LSD1 represses SESN2 expression. SESN2 expression was analyzed by qRT-PCR and Western 
blotting (a) using samples prepared from Tet-21/N cells treated with TCP or siLSD1 (100nM). (b) 
LSD1 binding to SESN2 chromatin. Cell treatments are indicated at the bottom of the figure. qPCR 
was performed with primers for SESN2 TSS, and -10kb. (c-f) Histone modifications at SESN2 
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chromatin; ChIPs were carried out using the indicated antibodies and analyzed with primers 
encompassing the TSS region and -10kb from TSS. Values from three independent ChIP assays 
are presented along with standard deviations, n=3. Changes in % input are shown normalized over 
IgG controls (*p < 0,05; **p<0,01; Student t test).  
 
Figure 5. 
LSD1 depletion-mediated autophagy does not rely on p53 activity. (a) Cell extracts from SK-N-BE 
(2) treated with TCP (1 mM) or SP2509 (1 µM) for 48 h were prepared and probed with specific 
SESN2 and LC3 antibodies. (b) SK-N-BE (2) were treated with different concentration of SP2509 
(0, 0,2, 0,5, 1 µM) for 48 h and protein extract were prepared and probed with the indicated 
antibody. Actinin was probed as loading control. 
 
Figure 6. 
LSD1 regulates autophagy through SESN2 expression. (a) SH-SY5Y were transfected with a 
SESN2 expression plasmid or empty vector and protein extract were prepared and stained with 
indicated antibody. (b) Localization of TFEB was analyzed in cells treated as described in A by 
immuno-staining with TFEB antibody. (c) SH-SY5Y cells were transfected with siRNA against 
SESN2 or scramble. 24h after transfection cells were treated with TCP or vehicle for 24h, and 
protein extract were probed with the indicated antibody. Actinin was probed as loading control. 
Graphs show quantitative analysis of western blot experiments. A mean value ± s.d. of four 
independent experiments is shown (*p<0,05; **p<0,005). (d) SH-SY5Y treated as described in c 
were fixed and stained with anti-TEFB and DAPI. Histograms show the percentage of TFEB 
nuclear translocation (mean ± s.d., n=200 cells). * p<0.0001. 
 
 
 
 
 
 
 16
REFERENCES 
1. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F et 
al. Autophagy in malignant transformation and cancer progression. EMBO J 2015; 34: 856-
80. 
2. Rebecca VW, Amaravadi RK. Emerging strategies to effectively target autophagy in 
cancer. Oncogene 2016; 35: 1-11. 
3. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular 
self-digestion. Nature 2008; 451: 1069-1075. 
4. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011; 
469: 323-335. 
5. Maiese K. Targeting molecules to medicine with mTOR, autophagy and neurodegenerative 
disorders. Br J Clin Pharmacol 2016; 82: 1245-1266. 
6. Jiang P, Mizushima N. Autophagy and human diseases. Cell Res 2014; 24: 69-79. 
7. Eisenberg-Lerner A, Kimchi A. The paradox of autophagy and its implication in cancer 
etiology and therapy. Apoptosis 2009; 14: 376-391. 
8. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between 
autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741-752. 
9. White E. The role for autophagy in cancer. J Clin Invest 2015; 125: 42-46. 
10. Sehgal AR, Konig H, Johnson DE, Tang D, Amaravadi RK, Boyiadzis M et al. You eat what 
you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia 2015; 29: 
517-525. 
11. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct 
phosphorylation of Ulk1. Nat Cell Biol 2011; 13: 132-141. 
12. Martina JA, Chen Y, Gucek M, Puertollano R. MTORC1 functions as a transcriptional 
regulator of autophagy by preventing nuclear transport of TFEB. Autophagy 2012; 8: 903-
914. 
13. Gallagher LE, Williamson LE, Chan EY. Advances in Autophagy Regulatory Mechanisms. 
Cells 2016; 5: 24 
14. Artal-Martinez de Narvajas A, Gomez TS, Zhang JS, Mann AO, Taoda Y, Gorman JA et al. 
Epigenetic regulation of autophagy by the methyltransferase G9a. Mol Cell Biol 2013; 33: 
3983-3993. 
15. Eisenberg T, Schroeder S, Andryushkova A, Pendl T, Küttner V, Bhukel A et al. 
Nucleocytosolic depletion of the energy metabolite acetyl-coenzyme a stimulates 
autophagy and prolongs lifespan. Cell Metab 2014; 19: 431-444. 
16. Lapierre LR, Kumsta C, Sandri M, Ballabio A, Hansen M. Transcriptional and epigenetic 
regulation of autophagy in aging. Autophagy 2015; 11: 867-880. 
17. Shy Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA et al. Histone demethylation 
 17
mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119: 941-953  
18. Lan F, Nottke AC, Shi Y. Mechanisms involved in the regulation of histone lysine 
demethylases. Curr Opin Cell Biol 2008; 20: 316-325.  
19. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH et al. LSD1 
demethylates repressive histone marks to promote androgen-receptor dependent 
transcription. Nature 2005; 437: 436-439.  
20. Wang J, Telese F, Tan Y, Li W, Jin C, He X et al. LSD1n is an H4K20 demethylase 
regulating memory formation via transcriptional elongation control. Nat Neurosci 2015; 
18:1256-1264 
21. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M et al. p53 is regulated by 
the lysine demethylase LSD1. Nature 2007; 449: 105-108.  
22. Kontaki H, Talianidis I. Lysine methylation regulates E2F1-induced cell death. Mol Cell 
2010; 39: 152-160.  
23. Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J et al. The lysine demethylase LSD1 
(KDM1) is required for maintenance of global DNA methylation. Nat Genet 2009; 41: 125-
129. 
24. Amente S, Lania L, Majello B. The histone LSD1 demethylase in stemness and cancer 
transcription programs. Biochim Biophys Acta 2013; 1829: 981-986. 
25. Ambrosio S, Amente S, Saccà CD, Capasso M, Calogero RA, Lania L, Majello B. LSD1 
mediates MYCN control of epithelial-mesenchymal transition through silencing of 
metastatic suppressor NDRG1 gene. Oncotarget 2017; 8:3854-3869  
26. Han X, Gui B, Xiong C, Zhao L, Liang J, Sun L et al. Destabilizing LSD1 by Jade-2 
promotes neurogenesis: an antibraking system in neural development. Mol Cell 2014; 55: 
482-494. 
27. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R et al. Lysine-specific 
demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for 
therapy. Cancer Res 2009; 69: 2065-2071. 
28. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K et al. Highly effective 
combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against 
human AML cells. Leukemia 2014; 28: 2155–2164. 
29. Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S et al. A lysosome-to-nucleus 
signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J 
2012; 31: 1095-1108. 
30. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring 
autophagy (3rd edition). Autophagy  2016; 12: 1-222. 
31. Mizushima N, Yoshimorim T, Levine B. Methods in Mammalian Autophagy Research. Cell 
2010; 140: 313-326. 
 18
32. Parmigiani A, Nourbakhsh A, Ding B, Wang W, Kim YC, Akopiants K et al. Sestrins inhibit 
mTORC1 kinase activation through the GATOR complex. Cell Rep 2014; 9: 1281-1291. 
33. Wolfson RL, Chantranupong L, Saxton RA, Shen K, Scaria SM, Cantor JR et al. Sestrin2 is 
a leucine sensor for the mTORC1 pathway. Science 2016; 351: 43-48. 
34. Periz G, Lu J, Zhang T, Kankel MW, Jablonski AM, Kalb R et al. Regulation of protein 
quality control by UBE4B and LSD1 through p53-mediated transcription. PLoS Biol 2015; 
13: e1002114; doi: 10.1371/journal.pbio.1002114. 
35. Cam M, Bid HK, Xiao L, Zambetti GP, Houghton PJ, Cam H. p53/TAp63 and AKT regulate 
mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent 
parallel pathways in the presence of DNA damage. J Biol Chem 2014; 289: 4083-4094. 
36. Maiuri MC, Malik SA, Morselli E, Kepp O, Criollo A, Mouchel PL et al. Stimulation of 
autophagy by the p53 target gene Sestrin2. Cell Cycle 2009; 8: 1571-1576. 
37. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and 
mTOR signaling. Cell 2008; 134: 451-60. 
38. Goldschneider D, Horvilleur E, Plassa LF, Guillaud-Bataille M, Million K, Wittmer-Dupret E 
et al. Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res 
2006; 34: 5603-5612. 
39. Amente S, Milazzo G, Sorrentino MC, Ambrosio S, Di Palo G, Lania L et al. Lysine-specific 
demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in 
neuroblastoma. Oncotarget 2015; 6: 14572-14583. 
40. Etani T, Suzuki T, Naiki T, Naiki-Ito A, Ando R, Iida K et al. NCL1, a highly selective lysine-
specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect. 
Oncotarget 2015; 6: 2865-2878. 
41. Feng S, Jin Y, Cui M, Zheng J. Lysine-Specific Demethylase 1 (LSD1) Inhibitor S2101 
Induces Autophagy via the AKT/mTOR Pathway in SKOV3 Ovarian Cancer Cells. Med Sci 
Monit 2016; 22: 4742-4748. 
42. Kim H, An S, Ro SH, Teixeira F, Park GJ, Kim C et al. Janus-faced Sestrin2 controls ROS 
and mTOR signalling through two separate functional domains. Nat Commun 2015; 6: 
10025. 
43. Zhang F, Kumano M, Beraldi E, Fazli L, Du C, Moore S et al. Clusterin facilitates stress-
induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival. 
Nat Commun 2014; 5: 5775. 
44. Füllgrabe J, Klionsky DJ, Joseph B. The return of the nucleus: transcriptional and 
epigenetic control of autophagy. Nat Rev Mol Cell Biol 2014; 15: 65-74. 
45. Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, Carnuccio R et al. Control of 
autophagy by oncogenes and tumor suppressor genes. Cell Death Differ 2009; 16: 87-93. 
 19
46. Zhang J, Ng S, Wang J, Zhou J, Tan SH, Yang N et al. Histone deacetylase inhibitors 
induce autophagy through FOXO1-dependent pathways. Autophagy 2015; 11: 629-642. 
47. Wei FZ, Cao Z, Wang X, Wang H, Cai MY, Li T et al. Epigenetic regulation of autophagy by 
the methyltransferase EZH2 through an MTOR-dependent pathway. Autophagy 2015; 11: 
2309-2322. 
48. Belounis A, Nyalendo C, Le Gall R, Imbriglio TV, Mahma M, Teira P et al. Autophagy is 
associated with chemoresistance in neuroblastoma. BMC Cancer 2016; 16: 891. 
 
 
siLSD1 (nM) 
E
R
K
1/
2 
(T
hr
 2
02
/T
yr
 2
04
) 
S
ta
t1
 (T
yr
 7
01
) 
S
ta
t3
 (T
yr
 7
05
) 
A
kt
 (T
hr
 3
08
) 
A
kt
 (S
er
 4
73
) 
A
M
P
K
α 
(T
hr
 1
72
) 
S
6 
(S
er
 2
35
/2
36
) 
m
TO
R
 (S
er
 2
44
8)
 
H
S
P
27
 (S
er
 7
8)
 
B
ad
 (S
er
 1
12
) 
p7
0 
S
6 
K
in
as
e 
(T
hr
 3
89
) 
P
R
A
S
40
 (T
hr
 2
46
) 
p5
3 
(S
er
 1
5)
 
p3
8 
(T
hr
 1
80
/T
yr
 1
82
) 
S
A
P
K
/J
N
K
 (T
hr
 1
83
/ T
yr
 1
85
) 
PA
R
P 
(A
sp
 2
14
) 
C
as
pa
se
-3
 (A
sp
 1
75
) 
G
S
K
-3
β 
(S
er
 9
) 
Figure 1 
P-rpS6 
rpS6 
P-p70S6K 
p70S6K 
0    12    24  
TCP SP2509 
0    12    24    
Ctrl 
a 
b 
TCP 
N
or
m
al
iz
ed
 d
en
si
ty
 (l
og
10
) 
S6 (Ser 235/236) 
p70 S6K (Thr 389) 
PRAS40 (Thr 246) 
 
 
P-rpS6 
rpS6 
P-p70S6K 
p70S6K 
–      +     TCP 
Actinin 
10 
1 
0,1 
c d 
P-rpS6 
rpS6 
Actinin 
LSD1 
0    50   100    
Actinin 100 kDa- 
32 kDa- 
32 kDa- 
70 kDa- 
70 kDa- 
100 kDa- 
32 kDa- 
32 kDa- 
 93 kDa- 
100 kDa- 
32 kDa- 
32 kDa- 
70 kDa- 
70 kDa- 
0 
20 
40 
60 
80 
100 
Figure 2  
a 
Ctrl 
48h  
SP2509 24 h 48 h 
Wash out 
DAPI 
TFEB 
Ctrl 
Tet-21/N 
d 
DAPI 
TFEB 
0    6   12   24 (h) 
TF
E
B
 n
uc
le
ar
 
tra
ns
lo
ca
tio
n 
%
 
TCP 
12h 24h 
TCP 
0 
20 
40 
60 
80 
100 12h 24h 
b 
Ctrl 
TCP 
SH-SY5Y 
DAPI 
TFEB 
0    6   12   24 (h) 
TF
E
B
 n
uc
le
ar
 
tra
ns
lo
ca
tio
n 
%
 
TCP 
6h 
6h 
0 
20 
40 
60 
80 
100 
TF
E
B
 n
uc
le
ar
 
tra
ns
lo
ca
tio
n 
%
 
–    +   24   48  SP2509 
Wash out (h) 
DAPI 
TFEB 
c 
Ctrl siLSD1 
0 
20 
40 
60 
80 
100 
TF
E
B
 n
uc
le
ar
 
tra
ns
lo
ca
tio
n 
%
 
–       +      siLSD1 
siLSD1 (nM) 
0 
10 
20 
30 
40 
50 
0 
10 
20 
30 
40 
50 
60 
Ctrl TCP TCP  
+ NH4Cl 
mRFP 
GFP 
Fl
uo
re
sc
en
t p
un
ct
a/
ce
ll 
Figure 3 
0    12    24   48    
TCP (h) 
LC3-I 
LC3-II 
Actinin 
a 
c 
R
ed
 p
os
iti
ve
 p
un
ct
a 
 
* 
Ctrl TCP TCP  
+ NH4Cl 
GFP mRFP 
Ctrl 
TCP 
TCP+  
NH4Cl 
overlay 
* 
100 kDa- 
14 kDa- 
16 kDa- 
0    50   100    
LC3-I 
LC3-II 
Actinin 100 kDa- 
14 kDa- 
16 kDa- 
LSD1 95 kDa- 
b 
0 
0,05 
0,1 
0,15 
0,2 
0,25 
0,3 
0,35 
-10Kb TSS 
0 
0,5 
1 
1,5 
2 
2,5 
3 
3,5 
4 
4,5 
-10Kb TSS 
0 
0,5 
1 
1,5 
2 * 
Figure 4 
a b 
LSD1 
H3Ac H3K27me3 
%
 in
pu
t 
%
 in
pu
t 
%
 in
pu
t 
0 
0,02 
0,04 
0,06 
0,08 
0,1 
0,12 
0,14 
0,16 
0,18 
0,2 
-10Kb TSS 
–     –     +     TCP 
–     +     –     siLSD1 
R
el
at
iv
e 
m
R
N
A 
le
ve
l 
** 
c 
SESN2 
Actinin 
** 
** 
** 
** ** 
** 
siLSD1 siCtrl Ctrl  TCP 
e 
H3K4me2 H3K9me2 
%
 in
pu
t 
%
 in
pu
t 
0 
1 
2 
3 
4 
5 
6 
–10Kb TSS 
* 
* 
U
nt
r 
TC
P 
si
C
trl
 
si
LS
D
1 
LSD1 
0 
0,05 
0,1 
0,15 
0,2 
-10Kb TSS 
d 
f 
100 kDa- 
93 kDa- 
54 kDa- 
Figure 5 
SESN2 
Actinin 
–     –     –     +    SP2509 
–     +     –     –    TCP 
P-p70S6K 
P-rpS6 
0    0,2    0,5   1    SP2509 (µM) 
 
LC3-I 
LC3-II 
Actinin 
p70S6K 
rpS6 
a b 
100 kDa- 
14 kDa- 
16 kDa- 
54 kDa- 70 kDa- 
70 kDa- 
32 kDa- 
32 kDa- 
100 kDa- 
0 
0,5 
1 
1,5 
Figure 6 
a 
–      +    SESN2-3XF 
SESN2 
Actinin 
P-rpS6 
rpS6 
b 
–                     +         SESN2-3XF 
DAPI 
TFEB 
c 
–      –      +      +      si-SESN2 
–      +      –      +      TCP 
SESN2 
Actinin 
P-rpS6 
rpS6 
d 
TF
E
B
 n
uc
le
ar
 
tra
ns
lo
ca
tio
n 
%
 Ctrl 
TCP 
Ctrl si-SESN2 TCP 
si-SESN2 
+TCP 
0 
20 
40 
60 
80 
100 
0 
20 
40 
60 
80 
100 
–     +     –    +     TCP 
–     –     +    +     siSESN2 
–            +            
si-SESN2 
TF
E
B
 n
uc
le
ar
 
tra
ns
lo
ca
tio
n 
%
 * 
* 
100 kDa- 
54 kDa- 
32 kDa- 
32 kDa- 
100 kDa- 
54 kDa- 
32 kDa- 
32 kDa- 
P
-r
pS
6/
rp
S
6 
le
ve
ls
 
** 
* 
0 
0,5 
1 
1,5 
P
-p
70
S
6K
/p
70
S
6K
 le
ve
ls
 
–     +     –    +     TCP 
–     –     +    +     siSESN2 
P-p70S6K 
p70S6K 70 kDa- 
70 kDa- 
DAPI 
TFEB 
* 
* 
Supplementary Figure 1 
LC3-I 
LC3-II 
Actinin 
SH-SY5Y 
–      +       TCP 
Supplementary Figure 1: SH-SY5Y cells were treated with TCP for 24 h and protein extract were 
prepared and probed using anti-LC3 antibody. Actinin was probed as loading control.  
100 kDa- 
14 kDa- 
16 kDa- 
Supplementary Figure 2: Screenshots of UCSC genome browser of SESN2 gene are shown. (A) and (B) the peaks represent the LSD1 
binding on the promoter region and TSS of SENS2 gene in mouse and human cells respectively. 
1-	
6-	
1-	
15-	
A 
B 
Supplementary Figure 2 
Supplementary Figure 3 
Supplementary Figure 3: Full scans of Western data. (*) Only in Fig. 1B,  for better results presentation, 
lanes have been separated into two panels that share the control sample (lane 3). 
Fig. 5b 
Fig. 5a 
Fig. 1b (*) Fig. 1c Fig. 1d Fig. 3a 
Fig. 6a Fig. 6c 
1   2   3   4   5 
Fig. 3b Fig. 4a 
Protein Used for Manufacturer 
 
Actinin WB sc-17829, Santa Cruz 
Sestrin 2 WB 10795-1-AP, Proteintech 
 
Phospho-S6 Ribosomial Protein WB 2215, Cell Signaling 
 
S6 Ribosomial Protein WB 2217, Cell Signaling 
 
Phospho-p70 S6 Kinase (Thr 389) WB 9205, Cell Signaling 
 
p70 S6 Kinase WB 2708, Cell Signaling 
 
LC3A/B WB 4108, Cell Signaling 
LSD1 ChIP, WB ab17721, Abcam 
TFEB 
 
IF 4240, Cell Signaling 
 
H3Ac ChIP 06-599, Millipore 
H3K27me3 
 
ChIP 
 
07-449, Millipore 
 
H3K4me2 ChIP ab32356, Abcam 
H3K9me2 ChIP ab1220, Abcam 
Table S1: antibodies and oligos used in this work!
Gene FW Rev 
 
qChiP SESN2 (–10Kb) 
 
CCAAGTTGTGAATGCAAAGG AGCCGAGATCAGGCCACT 
qChiP 
 
SESN2 (TSS) AGTCCCTCCAGGAACTGAAA GTCATTAGGGTTGCGTGATG 
qRT-PCR SESN2 GTGGACACCTCCGTGCTC GGTTCACCTCCCCATAATCA 
qRT-PCR 
 
GUSb GTGGGCATTGTGCTACCTC ATTTTTGTCCCGGCGAAC 
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Oncogenic	 activation	 of	 MYC	 proteins	 affects	 multiple	 intracellular	 pathways,	culminating	 in	 neoplastic	 transformation	 in	 many	 cell	 types	 (6-9).	 MYC	overexpression	is	involved	in	all	aspects	of	tumor	cell	biology	including	cellular	proliferation	 and	 growth,	 altered	 cellular	metabolism,	 cellular	 senescence	 and	differentiation	 blockage.	 Additionally,	 MYC	 orchestrates	 changes	 in	 the	 tumor	microenvironment,	 such	 as	 activation	 of	 angiogenesis	 and	 suppression	 of	 the	host	immune	response	(27,	28,	32,	48,	49).		Tumor	 maintenance	 machinery	 depends	 in	 large	 part	 on	 the	 accumulation	 of	mutations	 in	 the	 genome	 of	 neoplastic	 cells.	 Chromosomal	 instability	 is	 a	common	feature	of	many	human	cancers	(92).	As	in	the	case	of	other	oncogenes,	aberrant	 MYC	 activity	 is	 associated	 with	 the	 appearance	 of	 DNA	 damage-associated	markers	and	karyotypic	abnormalities	(41,	42).	This	phenomenon	can	be	explained	through	different	mechanisms.	First,	metabolic	effects	of	MYC	might	lead	 to	 DNA	 damage.	 Specifically,	 oxygen	 radicals	 produced	 following	 MYC	activation	could	lead	to	oxidative	base	modifications	(43).	An	additional	source	of	 MYC-induced	 DNA	 damage	 is	 replication	 stress,	 a	 poorly	 understood	perturbation	of	DNA	replication	(45).	 In	addition,	MYC	seems	to	be	 involved	in	the	modulation	of	DNA	repair	pathways.	 Indeed,	 it	has	been	demonstrated	that	MYC	 plays	 a	 role	 in	 regulating	 the	 repair	 of	 IR-induced	 DSBs,	 through	 direct	suppression	 of	 the	 NHEJ	 pathway	 and	 consequently	 enhanced	 chromosomal	 a	breaks.	(46,	47)	Findings	reported	in	this	study	add	further	support	to	the	role	of	MYC	proteins	in	DNA	 damage	 repair.	 In	 this	 work	 we	 used	 a	 dedicated	 cell	 system,	 in	 which	inducible	 specific	DSBs	may	occur,	 to	 investigate	 the	 role	of	MYC	oncoproteins	(MYC	 and	 MYCN)	 overexpression	 on	 repair	 of	 DNA	 double-strand	 breaks	 in	osteosarcoma	 and	 neuroblastoma	 cells.	 Our	 data	 show	 that	 damaged	 MYC	overexpressing	 cells	 undergo	 a	 prolonged	 cell	 cycle	 arrest	 and	 sustained	 DDR	response,	compared	to	cell	expressing	physiological	level	of	MYC,	suggesting	that	overexpression	 of	 MYC	 proteins	 impairs	 the	 wave	 of	 DSBs	 repair	 at	 the	 DNA	lesions.	We	found	that	MYC	does	not	prevent	appropriate	γ-H2AX	foci	formation,	indicating	that	aberrant	MYC	expression	does	not	affect	the	initial	recognition	of	DSBs.	 Proper	 DNA	 repair	 relies	 on	 the	 precise	 orchestration	 of	 DDR,	 DNA	replication	 and	 transcription,	 along	with	 cell	 cycle	 progression	 and	MYC	 could	
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interfere	with	 repair	 pathways	 at	 several	 different	 layers.	 First,	MYC	 regulates	expression	of	several	repair	factors	and	it	has	been	shown	to	interact	with	many	of	these,	such	as	TIP60,	DNA-PK	and	MRE11	(93,	94).	Replication	stress	induced	by	MYC	over-expression	could	 lead	to	an	aberrant	activation	of	DDR	at	sites	of	active	 DNA	 replication	 that	 impairs	 resolution	 of	 DNA	 repair.	 MYC	 has	 been	shown	 to	 have	 a	 profound	 impact	 on	 the	 global	 chromatin	 structure	 and	 it	 is	reasonable	to	think	that	MYC	proteins	could	influence	DNA	repair	substantially	influencing	 histone	modifications	 surrounding	DSBs	 (94-96).	Noteworthy,	 high	level	 of	 MYC	 proteins	 could	 abrogate	 DSB	 resolution	 altering	 the	 cell	 cycle	regulatory	machinery.		It	 is	 well	 established	 the	 interdependence	 between	 DNA	 repair	 and	 cell	 cycle	machineries.	Different	molecular	mechanisms	involved	in	DNA	repair	occurring	at	specific	cell	cycle	phases,	regulated	by	the	activity	of	cyclin-dependent	kinases	and	 by	 the	 cell	 cycle-dependent	 expression	 of	 required	 factors.	 DNA	 damage	induces	 cell	 cycle	 arrest,	 providing	 time	 for	 repair	 pathways	 before	 DNA	replication	 and	 segregation,	 whereas	 cells	 with	 unrepairable	 DNA	 lesions	undergo	permanent	cell	cycle	arrest	or	apoptosis	(97).		In	this	study	we	propose	that	cell	cycle	phase	 in	which	DNA	damage	occurs	do	not	interfere	with	DSBs	recognition	and	recruitment	of	repair	factors,	but	rather	that	DNA	damage	repair	competence	strictly	depend	on	cell	proliferative	status.	Thus,	 DNA	 repair	 is	 deeply	 reliant	 on	 fine	 regulation	 of	 cell-cycle	 progression	and	 disruption	 of	 these	 regulation	 systems	 can	 lead	 to	 defective	 DNA	 repair	pathways	and	DNA	damage	accumulation.		Control	of	cell	proliferation	 is	one	of	 the	major	rules	of	MYC	biology	and	 likely	the	most	relevant	for	its	oncogenic	activity	(28).	MYC	influences	all	levels	of	the	cell	cycle	regulatory	machinery	and	facilitates	transit	through	the	cell	cycle.	High	MYC	levels	accelerate	cell	division	and	mediate	unscheduled	entry	into	S-phase.	Moreover,	 MYC	 could	 lead	 to	 abrogation	 of	 DNA	 damage-induced	 cell	 cycle	checkpoint	 through	 the	 suppression	 of	 genes	 that	 encode	 inhibitors	 of	 cellular	proliferation,	 such	 as	 p21	 and	 p27	 (29-31).	 Thus,	 MYC	 overexpressing	 cells	experience	oxidative	stress,	damage	at	replication	forks	and	loss	of	DNA	damage-based	 checkpoints	 and	 repair	 capacity.	 Consequently,	 MYC	 pathological	activation	 may	 drive	 cells	 with	 unrepaired	 DNA	 damage	 into	 cell	 cycle	 and	
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escape	 from	 normal	 cellular	 barriers	 to	 establishment	 and	 tumorigenesis	maintenance.		Due	to	 its	ability	to	 impact	genetic	stability,	MYC	is	carefully	controlled	 in	non-pathological	 state	 through	 multiple	 genetic	 and	 epigenetically	 controlled	checkpoint	mechanisms.	Thus,	MYC	activation	alone	 is	 restrained	 from	causing	tumorigenesis,	unless	MYC	is	pathologically	activated	in	a	permissive	context;	in	this	case,	MYC	bypasses	control	mechanisms	and	may	lead	to	the	acquisition	of	additional	genomic	 lesions	that	could	enforce	many	of	 the	“hallmark”	of	cancer	and	 drive	 malignant	 transformation.	 This	 process	 can	 be	 enhanced	 by	compromised	 surveillance	 systems	 that	 normally	 monitor	 genomic	 integrity.	Consistent	 with	 this	 notion,	 genetic	 events	 that	 abrogate	 cell	 cycle	 arrest,	apoptosis,	 and	 senescence	 frequently	 occur	 during	 cancer	 progression	 and	synergize	 with	 MYC	 overexpression	 to	 create	 a	 permissive	 environment	 for	malignant	 transformation.	Examples	 include	 loss	of	p53	and	p19ARF	 functions	and	BCL-2	overexpression	(98-101).		A	 central	 tenet	 of	 molecular	 oncology	 asserts	 that	 these	 tumors,	 once	established,	 remain	 dependent	 on	 elevated	MYC	 levels	 to	 sustain	 proliferation	and	 viability	 and,	 therefore,	 could	 be	 treated	 by	 targeting	 MYC	 activity	 (57).	Supporting	 this	notion,	 knock-down	of	MYC	 in	 established	 tumors,	 using	 small	interfering	 RNA,	 short	 hairpin	 RNA	 and	 antisense	 oligonucleotides,	 appears	 to	reduce	cell	proliferation	and	induce	apoptosis;	in	transgenic	mouse	models	with	inducible	 MYC,	 when	 expression	 of	 the	 oncogene	 is	 switched	 off,	 tumor	 cells	undergo	apoptosis	(58-60);	 finally,	 in	vivo	expression	of	the	dominant	negative	inhibitor	of	MYC	heterodimerization,	OmoMYC,	has	resulted	in	tumor	regression	by	competing	with	MYC/MAX	for	binding	to	promoter	of	specific	genes	involved	in	MYC	driven	tumorigenesis	(102).	 	MYC	inactivation	could	lead	tumor	cells	to	lose	their	neoplastic	properties,	for	example	reducing	tumor	nutrient	providing	and	 restoring	differentiation	 signals.	 	 Beyond	 these	 effects,	MYC	 targeting	may	reduce	survive	capacity	also	due	 to	 the	consequent	restoration	of	some	critical	aspects	 of	 cell	 cycle	 checkpoint	 and	 repair	 functions	 that	 force	 damaged	 cells	into	either	senescence	or	apoptosis.	For	all	these	reasons,	targeting	MYC	activity	appears	 to	 have	 significant	 therapeutic	 value	 for	 cancers	 that	 involve	 gain	 of	function	 in	MYC.	Despite	many	efforts	have	been	made	(103),	 targeting	MYC	 is	
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not	 child’s	 play;	 since	 MYC	 lacks	 enzymatic	 activity	 or	 any	 deep	 pocket,	pharmacological	 targeting	 by	 small-molecules	 has	 limited	 applicability;	furthermore,	 at	 physiological	 level,	MYC	 acts	 as	 a	 vital	 transcription	 regulator,	and	its	inhibition	could	be	associated	with	high	toxicity.	Although	MYC	is	widely	considered	“undruggable”,	a	promising	approach	to	circumvent	blocking	MYC	is	selectively	 targeting	 chromatin	 modifiers	 that	 drive	 MYC-dependent	transcription.		MYC	 proteins	 orchestrate	 epigenetic	 alterations	 by	 recruitment	 of	 several	chromatin	complexes	that	activate	or	repress	transcription.	In	2010,	Amente	et	al.	demonstrated	that	LSD1	drives	transcription	of	MYC	target	genes	(71);	these	findings	 give	 rise	 to	 the	 interest	 of	 Majello	 laboratory	 on	 how	 LSD1/MYC	complex	 transcriptional	 activity	 could	 be	 exploited	 in	 the	 context	 of	 particular	types	 of	 MYC-driven	 cancers.	 Recently,	 we	 demonstrated	 that	 MYCN	 interacts	with	 LSD1	 and	 that,	 accordingly	 with	 LSD1	 role	 exerted	 in	 transcriptional	repression	events,	 the	MYCN/LSD1	complex	 is	 involved	 in	 repression	of	MYCN	target	 genes	 in	 neuroblastoma	 cell	 lines	 (91).	 Importantly,	 we	 reported	 that	LSD1	inhibition	reduces	neuroblastoma	cell	proliferation	and	causes	reactivation	of	p21,	CLU	and,	plausibly,	other	potential	 tumor	suppressor	genes	 involved	 in	MYCN-driven	 oncogenesis	 with	 therapeutic	 effects,	 suggesting	 that	 LSD1	inhibition	 could	 be	 therapeutically	 used,	 alone	 or	 in	 combination	 with	 other	therapeutic	tools,	to	counteract	MYCN-amplified	neuroblastomas.	LSD1	 has	 been	 shown	 to	 be	 involved	 in	 maintaining	 the	 undifferentiated,	malignant	 phenotype	 of	 neuroblastoma	 cells	 and	 its	 overexpression	 correlated	with	 aggressive	 disease,	 poor	 differentiation	 and	 infaust	 outcome	 (85),	suggesting	 that	 the	 employ	 of	 LSD1	pharmacological	 inhibitors	 could	 be	 taken	under	 consideration	 as	 a	 valid	 therapeutic	 approach	 directed	 against	neuroblastomas	with	MYCN	amplification.	For	these	reasons	our	work	has	been	focused	 on	 understanding	 of	 LSD1	 role	 in	 MYCN-driven	 transcription,	 and	uncovering	its	potential	as	a	new	perspective	for	therapy	in	neuroblastoma.	We	found	 that,	 in	 neuroblastoma	 cells,	 LSD1	 is	 deeply	 involved	 in	 two	 major	processes	 in	 cancers,	 epithelial-mesenchymal-transition	 and	 mTORC-mediated	autophagy.	Recent	observations	 indicate	 that	 these	 two	 important	processes	 in	cancer	 are	 linked	 in	 an	 intricate	 relationship	 (104).	 While	 EMT	 requires	
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autophagy	 to	support	viability	of	potentially	metastatic	cancer	cells,	 autophagy	acts	to	prevent	EMT.	Indeed,	 it	has	been	shown	that	 induction	of	autophagy	by	mTOR	 pathway	 inhibition	 leads	 to	 reduced	 migration	 and	 invasion	 in	glioblastoma	cells,	while	autophagy	impairment	results	in	enhanced	cell	motility	and	invasiveness	(104).	Moreover,	activation	of	the	autophagic	process	leads	to	SNAIL	 degradation,	 a	 critical	 transcription	 factors	 which	 promotes	 the	 EMT	process.	Here	we	propose	the	LSD1-specific	transcriptional	regulation	as	a	novel	link	between	EMT	and	autophagy.		We	 described	 a	 novel	 role	 for	 MYCN/LSD1	 complex	 in	 migration	 and	invasiveness	 of	 neuroblastoma	 cells	 through	 the	 transcriptional	 control	 of	 the	metastatic	 suppressor	 NDRG1.	 Neuroblastoma	 is	 a	 high	 metastatic	 tumor	 and	MYCN	overexpression	correlates	with	 invasive	and	metastatic	behavior.	 	MYCN	contributes	 to	 all	 facets	 of	 metastasis:	 adhesion,	 motility,	 invasion,	 and	degradation	 of	 surrounding	 matrices	 (105).	 We	 propose	 that	 LSD1	pharmacological	 targeting	 by	 small	 molecules	 could	 modulate	 cell	 migration	capability	 and	 invasiveness	 of	 cancer	 cells	 through	 NDRG1	 de-repression	 and	impair	the	ability	of	MYCN-amplified	neuroblastomas	to	metastasize.		Intriguingly,	we	found	that	LSD1	inhibition	also	lead	to	NDRG1	phosphorylation	at	 Thr346.	 Phosphorylation	 of	 NDRG1	 is	 mediated	 through	 the	serum/glucocorticoid	regulated	kinase	1	(SGK1)	and	glycogen	synthase	kinase	3	beta	 (GSK3b),	 and	 seems	 to	 be	 under	 control	 of	 the	 Mammalian	 target	 of	rapamycin	 complex	 2	 (mTORC2)	 cascade	 (106). 	 The	 impact	 of	 NDRG1	phosphorylation	 is	 largely	 unknown;	 NDRG1	 phosphorylation	 mediated	 by	LSD1-inhibition	may	be	related	to	the	modulation	of	the	Wnt/β-catenin	signaling	pathway	and	contribute	 to	NDRG1	anti-metastatic	effects	 in	NB	cells.	However,	additional	 investigation	 is	 needed	 to	unequivocally	 determine	whether	NDRG1	phosphorylation	 has	 a	 role	 in	 the	 modulation	 of	 NDRG1	 anti-metastatic	functions.	Moreover,	 we	 found	 that	 LSD1	 inhibition	 triggers	 autophagy	 through	 the	impairment	 of	 the	 Mammalian	 target	 of	 rapamycin	 complex	 1	 (mTORC1)	cascade.	 mTORC1	 has	 essential	 functions	 in	 translational	 control,	 metabolism,	proliferation	and	tumorigenesis,	and	proteins	involved	in	mTORC1	signaling	are	frequently	altered	in	human	cancers	(107,	108).	We	identified	Sestrin2	(SESN2)	
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as	 an	 LSD1	 negative	 transcriptional	 target.	 SESN2	 acts	 as	 mTORC1	 inhibitor	through	the	GATOR	complex	via	interaction	with	GATOR2	(109).	We	found	that	SESN2	 enhanced	 expression	 suffices	 to	 promote	 autophagy	 in	 neuroblastoma	cells	 and	 SESN2	 silencing	 attenuates	 mTORC1	 suppression	 and	 autophagy	induction	 by	 LSD1	 inhibition,	 indicating	 that	 SESN2	 has	 a	 critical	 role	 in	 the	autophagy	activation	mediated	by	LSD1	depletion.	Emerging	evidences	has	established	mTORC1	as	a	major	link	in	development	and	progression	 of	 neuroblastoma.	 mTORC1	 inhibition	 seems	 to	 have	antiproliferative	effects	and	increased	apoptosis	 in	neuroblastoma	cells	 in	vitro	(110).	 Additionally,	 mTOR	 inhibition	 has	 been	 shown	 to	 inhibit	 angiogenesis	decreasing	VEGF-A	secretion	and	downregulate	expression	of	MYCN	and	cyclin	D1	 proteins.	 (111).	 Indeed,	 mTORC	 pathway	 seems	 to	 be	 involved	 in	 MYC	proteins	stability.	Turnover	of	MYC	 is	 largely	dependent	on	phosphorylation	at	T58	and	S62;	phosphorylation	at	S62	stabilizes	MYC,	and	priming	these	proteins	for	 phosphorylation	 at	 T58	 via	 GSK3b;	 dephosphorylation	 of	 S62	 via	 protein	phosphatase	2A	(PP2A)	sensitizes	MYC	phosphorylated	at	T58	to	bind	F-box	and	WD	 repeat	 domain-containing	 7	 (FBW7),	 leading	 to	 the	 ubiquitination	 and	degradation	 in	 the	 proteasome.	 	 It	 has	 been	 shown	 that	 AMBRA1,	 a	 pro-autophagic	 mTORC	 downstream	 target	 protein,	 promotes	 the	 interaction	between	MYC	and	its	phosphatase	PP2A,	facilitating	the	dephosphorylation	and	degradation	 of	 the	 proto-oncogene	 MYC	 (112).	 These	 evidences	 suggest	 that	mTORC1	 inhibition	 represent	 a	 viable	 strategy	 to	 targeting	 MYCN	 amplified	neuroblastoma.	However,	the	induction	of	autophagy	may	be	a	double-edged	sword	in	cancer:	it	represents	a	suppressive	mechanism	against	tumor	formation,	counteracting	the	accumulation	of	damaged	organelles	and	misfolded	proteins;	on	the	other	hand,	autophagy	 provides	 a	 survival	 strategy	 for	 established	 tumor	 growth	 and	maintenance	 (113).	 Thus,	 autophagy	 might	 have	 different	 effects	 in	 tumors	depending	on	the	cell	type	and	the	stage	of	progression.	Recent	studies	showed	that	 autophagy	 predicts	 resistance	 to	 chemotherapy	 and	 survival	 in	neuroblastoma	 (114)	 and	 this	 should	 be	 taken	 in	 consideration.	 Future	investigations	may	clarify	whether	combinatory	LSD1	and	autophagy	inhibition	
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could	be	a	strategy	to	increase	cytotoxic	effects	and	improve	the	efficacy	of	LSD1	inhibitors	in	neuroblastoma	cells.			Concluding,	 this	 study	 expands	 our	 knowledge	 about	 the	 impact	 of	 MYC	oncogenes	alterations	on	damage	response	and	repair	networks.	Moreover,	our	findings	establish	the	major	role	of	 the	MYCN/LSD1	complex	 in	neuroblastoma	and	 elucidate	 the	 critical	 function	 of	 LSD1	 in	 the	 control	 of	 many	 important	aspects	of	cell	biology,	through	transcription	regulation	of	specific	target	genes,	suggesting	 that	 LSD1	 inhibition	 may	 have	 strong	 therapeutic	 relevance	 to	counteract	MYCN-driven	oncogenesis.		Future	elucidation	of	MYC-driven	 transcriptional	network	 in	 cancers	may	have	important	 implication	 for	 the	 development	 of	 new	 therapeutic	 approaches	directed	against	malignancies	with	deregulated	MYC.			
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